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A B S T R A C T
Background
During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels. This
can lead to the development of various perimenopausal and postmenopausal symptoms (for example hot flushes, night sweats, vaginal
dryness). Dehydroepiandrosterone (DHEA) is one of the main precursors of androgens, which in turn are converted to testosterone
and estrogens. It is possible that the administration of DHEAmay increase estrogen and testosterone levels in peri- and postmenopausal
women to alleviate their symptoms and improve general wellbeing and sexual function (for example libido, dyspareunia, satisfaction).
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety. This review should clearly outline the
evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of
randomised controlled trials.
Objectives
To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal
phase.
Search methods
The databases that we searched (3 June 2014) with no language restrictions applied were the Cochrane Menstrual Disorders and Sub-
fertility Group Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, PsycINFO,
CINAHL and LILACS. We also searched conference abstracts and citation lists in the ISI Web of Knowledge. Ongoing trials were
searched in the trials registers. Reference lists of retrieved articles were checked.
Selection criteria
We included randomised controlled trials comparing any dose and form of DHEA by any route of administration versus any other
active intervention, placebo or no treatment for a minimal treatment duration of seven days in peri- and postmenopausal women.
Data collection and analysis
Two authors independently extracted data after assessing eligibility for inclusion and quality of studies. Authors were contacted for
additional information.
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Main results
Twenty-eight trials with 1273 menopausal women were included in this review. Data could be extracted from 16 trials to conduct
the meta-analysis. The overall quality of the studies was moderate to low with the majority of studies that were included in the meta-
analysis having reasonable methodology. Compared to placebo, DHEA did not improve quality of life (standardised mean difference
(SMD) 0.16, 95% confidence interval (CI) -0.03 to 0.34, P = 0.10, 8 studies, 287 women (132 from parallel and 155 from crossover
trials), I² = 0%, moderate quality evidence; one trial of the nine that reported on this outcome was removed in a sensitivity analysis as
it was judged to be at high risk of bias). DHEA was found to be associated with androgenic side effects (mainly acne) (odds ratio (OR)
3.77, 95% CI 1.36 to 10.4, P = 0.01, 5 studies, 376 women, I² = 10%, moderate quality evidence) when compared to placebo. No
associations were found with other adverse effects. It was unclear whether DHEA affected menopausal symptoms as the results from the
trials were inconsistent and could not easily be pooled to provide an overall effect due to different types of measurement (for example
continuous, dichotomous, change and end scores). DHEA was found to improve sexual function (SMD 0.31, 95% CI 0.07 to 0.55,
P = 0.01, 5 studies, 261 women (239 women from parallel trials and 22 women from crossover trials), I² = 0%; one trial judged to be
at high risk of bias was removed during sensitivity analysis) compared to placebo.
There was no difference in the acne associated with DHEA when comparing studies that used oral DHEA (OR 2.16, 95% CI 0.47
to 9.96, P = 0.90, 3 studies, 136 women, I² = 5%, very low quality evidence) to one study that used skin application of DHEA (OR
2.74, 95% CI 0.10 to 74.87, P = 0.90, 1 study, 22 women, very low quality evidence). The effects did not differ for sexual function
when studies using oral DHEA (SMD 0.11, 95% CI -0.13 to 0.35, P = 0.36, 5 studies, 340 women, I² = 0) were compared to a study
using intravaginal DHEA (SMD 0.42, 95% CI 0.03 to 0.81, 1 study, 218 women). Test for subgroup differences: Chi² = 1.77, df = 1
(P = 0.18), I² = 43.4%. Insufficient data were available to assess quality of life and menopausal symptoms for this comparison.
There were insufficient data available to compare the effects of DHEA to hormone therapy (HT) for quality of life, menopausal
symptoms, and adverse effects. No large differences in treatment effects were found for sexual function when comparing DHEA to HT
(mean difference (MD) 1.26, 95% CI -0.21 to 2.73, P = 0.09, 2 studies, 41 women, I² = 0%).
Authors’ conclusions
There is no evidence that DHEA improves quality of life but there is some evidence that it is associated with androgenic side effects.
There is uncertainty whether DHEA decreases menopausal symptoms, but DHEA may slightly improve sexual function compared
with placebo.
P L A I N L A N G U A G E S U M M A R Y
Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Review question
Cochrane authors investigated whether DHEA (dehydroepiandrosterone) supplementation is safe and improves quality of life,
menopausal symptoms, and sexual function for women in the peri- or postmenopausal phase.
Background
During menopause a fluctuation and eventually a decrease in estrogen levels occur. These hormonal changes can cause women to
experience peri- or postmenopausal symptoms (for example flushes, night sweats, vaginal dryness). DHEA is a so-called precursor
hormone which is converted by the body to estrogens and androgens. It is possible that supplementation with DHEA may increase
estrogen and testosterone levels in peri- and postmenopausal women to decrease menopausal symptoms and improve general wellbeing
and sexual function.
The aim of this review was to assess the effectiveness and safety of DHEA in menopausal women, comparing any dose and form of
DHEA by any route of administration versus any other treatment, placebo, or no treatment for a minimum treatment duration of
seven days.
Search date
The evidence was current to 3 June 2014.
Study characteristics
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A total of 28 randomised controlled trials were included, with a total of 1273 menopausal women. Over 95% of the study populations
were postmenopausal women. Women’s ages ranged from 36 to 80 years. Treatment duration varied from one week to one year. In
more than 80% of the trials DHEA was administered orally with the daily doses varying between 10 mg and 1600 mg.
Key results
We found no evidence that DHEA improves quality of life. There was some evidence that it was associated with androgenic side effects
(for example acne, unwanted hair growth (hirsutism)). It was uncertain whether DHEA decreased menopausal symptoms, but DHEA
may have slightly improved sexual function.
Quality of the evidence
The quality of the evidence was moderate for both quality of life and side effects. We downgraded the quality of evidence based on the
lack of data on randomisation, allocation, or blinding; small study sizes overall; and limited data available.
3Dehydroepiandrosterone for women in the peri- or postmenopausal phase (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
DHEA compared to control (placebo or no treatment)
Population: women in the peri- or postmenopausal phase
Settings:
Intervention: DHEA
Comparison: control (placebo or no treatment)
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded for imprecision due to wide conf idence intervals












































































































B A C K G R O U N D
Description of the condition
The menopause is said to have occurred once there is perma-
nent cessation of menstruation. Prior to the final menstruation
there is usually a gradual reduction in the frequency of men-
strual periods, known as the perimenopause. Postmenopause is
defined as the period of time following on from 12 months af-
ter a woman has experienced her last menstruation. During per-
imenopause there is a fluctuation in estrogen levels due to de-
creasing ovarian follicular response (Hoffman 2012; Rosen 2011;
Speroff 2005). Most women become menopausal between 45
and 55 years of age, however there are also women who reach
menopause at an earlier age for various reasons (for example pre-
mature ovarian insufficiency (sometimes due to chemotherapy)
or bilateral oophorectomy). Menopausal women can develop a
range of symptoms including vasomotor symptoms such as hot
flushes and night sweats,and vaginal atrophy leading to vaginal
dryness and dyspareunia, which can impact on sexual function
(Genazzani 2002; Speroff 2005). Hormone therapy (HT) (estro-
gen alone or in combination with a progestin) is currently indi-
cated for the treatment of menopausal symptoms. However, HT
has been associated with a significant increase in the risk of vari-
ous conditions including breast cancer, venous thromboembolism
and stroke (Cameron 2005; Manson 2013; Marjoribanks 2012;
Rossouw 2002; State-of-the-Science-Panel 2005; Taylor 2011).
Description of the intervention
Dehydroepiandrosterone (DHEA) is one of the main precursor
sex steroids. DHEA is synthesized from cholesterol in the zone
reticularis of the adrenal gland. It is converted to estrogens and
testosterone by steroidogenic enzymes expressed in peripheral tis-
sues such as the skeleton, breasts and ovary (Figure 1). DHEA
peaks at the age of 25 years and then slowly declines to approx-
imately 30% of the initial levels at postmenopause (Genazzani
2002; Rosen 2011; Speroff 2005). In the United States of Amer-
ica (USA) DHEA can be purchased without prescription but in
most countries it is only available by prescription. DHEA may
be administered orally, intravaginally or by alternative routes of
administration (for example transdermal patches).
Figure 1. Biosynthesis of DHEA and estrogens.
AsDHEA and eventually estrogen can be synthesized from choles-
terol, levels of circulating estrogen and DHEA may differ in over-
weight women (body mass index (BMI) > 25 kg/m2) compared
to women with a normal weight (BMI 18 to 25 kg/m2) or un-
derweight women (BMI < 18 kg/m2) (Buster 2000; Miller 2002).
Therefore, administered DHEA may have differing effects on
women who are over- or underweight compared to those with a
normal BMI.
Some inflammatory diseases (for example systemic lupus erythe-
matosus, Sjögren syndrome) are associated with low circulating
DHEA levels (Sawalha 2008). DHEA levels may correlate with
disease activity, therefore DHEA supplementation may have a dif-
ferent effect in women with and without inflammatory disease.
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How the intervention might work
Due to a fluctuation and eventual decrease in estrogen levels (estra-
diol in particular), women can develop various perimenopausal
and postmenopausal symptoms. While the body is adjusting to
these hormonal changes womenmay experience symptoms such as
hot flushes and night sweats. Low estradiol levels can cause vaginal
dryness, which may lead to diminished sexual function (Hoffman
2012; Speroff 2005). All of these symptoms may cause a decrease
in the general wellbeing of peri- and postmenopausal women. It is
suggested that testosterone increases sexual desire and sexual func-
tion (Davis 2008; Pluchino 2013). As DHEA is one of the main
precursors of androgens, which in turn are converted to testos-
terone and estrogens (Figure 1) (Simpson 2003; Vanson 1996), it
is possible that the administration of DHEA may increase estro-
gen and testosterone levels in peri- and postmenopausal women
to alleviate their symptoms and improve general wellbeing (Buster
2000; Davis 2008; Mayo 2002; Pluchino 2013; Raven 2007).
The effects of DHEA on menopausal women may differ from
HT because of the additional androgenic effect of DHEA (Dobs
2002; Labrie 2005). In postmenopausal women DHEA has been
hypothesized to increase the incidence of breast cancer and caution
is advised. However, there have been limited studies on this subject
and the results of these studies are inconsistent (Morris 2001;
Schwartz 2006; Shilkaitis 2005; Stoll 1999). No other serious
adverse effects of DHEA have been described in the published
literature. Doses of 50 mg and above have shown androgenic side
effects (for example acne and increased hair growth) (Kroboth
1999; Panjari 2010).
Different effects of DHEA have been described using different
routes of administration (Casson 1996). Intravaginal administra-
tion of DHEA has been reported to have a better effect on al-
leviating the symptom of vaginal atrophy and improving sexual
function than oral administration of DHEA (Goel 2011).
Why it is important to do this review
Treatment with DHEA is controversial as there is uncertainty
about its effectiveness and safety (Buster 2000; Panjari 2010;
Raven 2007). Inconsistent findings have been published on the
effects of DHEA in menopausal women and much of the data
from clinical trials are limited by small sample sizes and short du-
ration of treatment (Cameron 2005; Panjari 2010). This review
should clearly outline the evidence for DHEA in the treatment of
menopausal symptoms and evaluate its effectiveness and safety by
combining the results of randomised controlled trials.
O B J E C T I V E S
To assess the effectiveness and safety of administering DHEA
to women with menopausal symptoms in the peri- or post-
menopausal phase.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Published and unpublished randomised controlled trials (RCTs)
were eligible for inclusion. We excluded non-randomised studies
(for example studies with evidence of inadequate sequence genera-
tion such as alternate days, patient numbers) as they are associated
with a high risk of bias.
Types of participants
Menopausal women: women who are going through the
menopausal transition or women who are postmenopausal.
Perimenopause: the period of menopausal transition leading to a
natural menopause, which ends 12 months after the final men-
strual period. A specific staging can be found in the Stages of
Reproductive Aging Workshop (STRAW) + 10 criteria (Harlow
2013).
Postmenopause: after one year with absence of menses and with
follicle stimulating hormone (FSH) levels > 40 IU/L; also women
following surgical menopause (removal of both ovaries) will be
included.
Types of interventions
Trials comparing any dose and form of DHEA by any route of
administration versus any other active intervention, placebo or no
treatment were eligible for inclusion. Treatment duration was at
least one week.
Types of outcome measures
Primary outcomes
Effectiveness
General wellbeing or quality of life (as defined by different scoring
scales for example the Psychological General Well-Being Index
(PGWB), theMedicalOutcomes Study 36-item short form survey
(SF-36), Life Satisfaction Index-Z (LSI-Z), Satisfaction with Life
Scale (SWLS), Health Status Questionnaire (HSQ), Quality of
Life scale (QoL), Beck Depression Inventory (BDI), Hamilton
Depression Scale (HDRS)).
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Any adverse effects
Adverse effects were described as they had been reported in the
studies (for example events of breast cancer, cardiovascular events
or androgenic side effects).
Secondary outcomes
Menopausal symptoms (for example vaginal dryness, hot flushes,
night sweats) defined by different scoring scales including the
Menopause Rating Scale (MRS) (Heinemann 2004), Kupperman
Index (KI) and Greene Climacteric Scale (GCS).
Sexual function (for example libido, dyspareunia, satisfaction)
defined by different scoring scales including the Female Sex-
ual Function Index (FSFI), Brief Index of Sexual Functioning
for Women (BISF-W), Changes in Sexual Functioning Ques-
tionnaire (CSFQ), Derogatis Interview for Sexual Functioning
(DISF/DISF-SR), Golombok-Rust Inventory of Sexual Satisfac-
tion (GRISS).
Search methods for identification of studies
We searched for all published and unpublished randomised
controlled trials (RCTs) investigating the effects of DHEA in
menopausal women, without language restriction and in con-
sultation with the Menstrual Disorders and Subfertility Group
(MDSG) Trials Search Co-ordinator. We used EndNote for the
bibliographic management of references found in the search out-
put.
Electronic searches
(1) We searched the following electronic databases, trial regis-
ters and websites from inception to the present: Menstrual Disor-
ders and Subfertility Group (MDSG) Specialised Register of con-
trolled trials (Appendix 1), the Cochrane Central Register of Con-
trolled Trials (CENTRAL) in The Cochrane Library (Appendix 2),
MEDLINE (Appendix 3), EMBASE (Appendix 4), PsycINFO
(Appendix 5) andCINAHL (Appendix 6). TheMEDLINE search
has been combinedwith theCochrane highly sensitive search strat-
egy for identifying RCTs which appears in the Cochrane Hand-
book for Systematic Reviews of Interventions (Version 5.0, chapter 6,
6.4.11). The EMBASE, PsycINFO and CINAHL searches were
combined with trial filters developed by the Scottish Intercol-
legiate Guidelines Network (SIGN) (www.sign.ac.uk/methodol-
ogy/filters.html#random).
(2) Other electronic sources of trials were included (Appendix 7).
• Trial registers for ongoing and registered trials:
o www.clinicaltrials.gov (a service of the US National Institutes of
Health),
owww.who.int/trialsearch/Default.aspx (WorldHealthOrganiza-
tion International Clinical Trials Registry Platform search portal).
• DARE (Database of Abstracts of Reviews of Effects) in The
Cochrane Library at http://onlinelibrary.wiley.com/o/cochrane/
cochrane˙cldare˙articles˙fs.html (for reference lists from relevant
non-Cochrane reviews).
• Web of Knowledge at http://wokinfo.com/ (another source of
trials and conference abstracts).
• OpenGrey at www.opengrey.eu/ for unpublished literature from
Europe.
• LILACS database at http://regional.bvsalud.org/php/index.php?
lang=en (for trials from the Portuguese and Spanish speaking
world).
• PubMed and Google (for recent trials not yet indexed in MED-
LINE).
Searching other resources
3.We handsearched reference lists of articles retrieved by the search
and contacted experts in the field to obtain additional data. We
also handsearched relevant journals and conference abstracts that
are not covered in the MDSG Specialised Register, in liaison with
the Trials Search Co-ordinator.
Data collection and analysis
Selection of studies
Only RCTs studying the effectiveness and safety of DHEA ad-
ministration to menopausal women were included. Data from
crossover trials was included and analysed using the generic inverse
variance method. The authors independently scanned the titles
and abstracts of the articles retrieved by the search. Full texts of
potentially eligible studies were retrieved and examined indepen-
dently by the authors. The full text articles were selected according
to the inclusion criteria. In the case of doubts or disagreement be-
tween the two authors, a third author was consulted to gain con-
sensus on whether to include the trial or not. The selection process
was documented with a Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) flow chart.
Data extraction and management
The data obtained were extracted by two review authors. In the
case of a disagreement between the two authors, a third author
was consulted to achieve consensus. Data were extracted by using
a data extraction form designed and pilot tested by the authors.
If studies were reported in multiple publications, the data were
extracted from the different publications andwere combined into a
single data extraction form so no data wentmissing. The following
characteristics of included studies were included in the extraction
form: methods, participants, interventions and outcomes.
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Assessment of risk of bias in included studies
To assess the risk of bias in the included studies the Cochrane
Collaboration’s recommended tool is a domain based evaluation.
We used this tool to assess the following domains and divide the
assessments into high, unclear or low risk of bias.
• Selection bias (random sequence generation, allocation
concealment).
• Performance bias (blinding of participants and personnel).
• Detection bias (blinding of outcome assessment).
• Attrition bias (incomplete outcome data).
• Reporting bias (selective reporting).
• Other bias (other sources of bias).
Disagreements were resolved by discussion or by a third review
author. We described all judgements fully and presented the con-
clusions in the risk of bias table, which was incorporated into the
interpretation of review findings by means of sensitivity analyses
(see below).We took care to search for within-trial selective report-
ing, such as trials failing to report obvious outcomes, or reporting
them in insufficient detail to allow inclusion. We sought published
protocols and compared the outcomes between the protocol and
the final published study.
Measures of treatment effect
For dichotomous datawe used the numbers of events in the control
and intervention groups of each study to calculate the Mantel-
Haenszel odds ratios (ORs). For continuous data, if all studies
reported the same outcomeswe calculatedmeandifferences (MDs)
between treatment groups. If similar outcomes were reported on
different scales, we calculated the standardised mean difference
(SMD).We treated ordinal data as continuous data.We calculated
95% confidence intervals (CIs) for all outcomes. Where data for
the calculation ofORs orMDswere not available we used themost
detailed numeric data available that facilitated similar analyses of
included studies.
Unit of analysis issues
The primary analysis was done per woman randomised. Data that
did not allow valid analysis were briefly summarized in an addi-
tional table and were not included in the meta-analysis. Statisti-
cal advice was sought regarding the analysis of crossover trials to
facilitate the appropriate inclusion of crossover data in the meta-
analysis.
Dealing with missing data
If relevant data were missing from an included study the original
investigators of the trial were contacted to request themissing data
from them. If the original investigator could not be contacted or
did not reply, we determined whether to include or exclude the
trial or only include the data that were fully available. If variance
data for the primary outcome were missing (for example SD) then
these were imputed from the range where possible.
Assessment of heterogeneity
We considered whether the clinical and methodological charac-
teristics of the included studies were sufficiently similar for meta-
analysis to provide a clinically meaningful summary. Statistical
heterogeneity was assessed by determining the I² statistic. We as-
sumed that there was substantial heterogeneity when I² was cal-
culated to be greater than 50% (Higgins 2003; Higgins 2011).
Assessment of reporting biases
In view of the difficulty of detecting and correcting for publication
bias and other reporting biases, the authors aimed to minimise
their potential impact by ensuring a comprehensive search for
eligible studies and by being alert to duplication of data. If there
were 10 or more studies in an analysis, we planned to use a funnel
plot to explore the possibility of small study effects (a tendency
for estimates of the intervention effect to be more beneficial in
smaller studies); this however was not performed.
Data synthesis
Where sufficient data were available, data were combined for the
primary outcomes by using a fixed-effect model. The following
comparisons were made:
1. DHEA versus control (placebo or no intervention);
2. Oral versus other routes of administration (e.g. intravaginal
DHEA, transdermal patches);
3. DHEA versus HT (estrogen and progesterone in combination
(ET + P) and separately (ET or P), androgen therapy or tibolone);
4. DHEA versus any other medical treatment (e.g. antidepressants
or clonidine);
5. DHEA versus any other non-medical treatment (e.g. non-med-
ical therapies such as acupuncture or complementary therapies).
Subgroup analysis and investigation of heterogeneity
Where sufficient data were available, we conducted subgroup anal-
yses for the primary outcomes to determine the separate evidence
within the following subgroups:
1. BMI (< 18 kg/m2, 18 to 25 kg/m2, > 25 kg/m2);
2. menopausal status (peri- or postmenopausal);
3. duration of the intervention (≤ 6 weeks, > 6 to 26 weeks, > 26
weeks);
4. younger female (< 40 years, after bilateral oophorectomy or
premature ovarian insufficiency);
5. hyposexual desire disorder or low libido;
6. inflammatory disease (e.g. systemic lupus erythematosus (SLE),
Sjögren syndrome);
7. breast cancer.
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In addition to the abovewe conducted a post hoc subgroup analysis
by route of administration. Initially we had planned to look at
studies comparing different routes but as there were no studies
with this comparison we have opted to do a subgroup analysis to
look at this evidence.
If we detected substantial heterogeneity we explored possible ex-
planations in sensitivity analyses. We took any statistical hetero-
geneity into account when interpreting the results, especially if
there was any variation in the direction of effect.
Sensitivity analysis
We conducted sensitivity analyses for the primary outcomes to
determine whether the conclusions were robust to arbitrary deci-
sions made regarding the eligibility and analysis of studies. These
analyses were included and considered whether the review conclu-
sions would have differed if:
1. eligibility was restricted to studies without high risk of bias;
2. a random-effects model had been adopted;
3. alternative imputation strategies had been implemented;
4. the summary effect measure was relative risk (RR) rather than
odds ratio (OR).
We also conducted a post hoc sensitivity analysis by removing
a study at high risk of bias from the sexual function secondary
outcome.
Overall quality of the body of evidence: summary of
findings table
We prepared a summary of findings table using GRADEpro or
Guideline Development Tool software. This table evaluated the
overall quality of the body of evidence for the primary review
outcomes (general wellbeing or quality of life and adverse effects)
using theGRADE criteria (study limitations, consistency of effect,
imprecision, indirectness and publication bias). Judgements about
the quality of evidence (high,moderate or low) have been justified,
documented and incorporated into the reporting of results for
each outcome.
R E S U L T S
Description of studies
Results of the search
The search retrieved a total of 2277 titles with abstracts. These
were screened to identify whether the intervention and study pop-
ulations met the inclusion criteria. After this initial screening we
retrieved the full text of 76 trials for assessment of eligibility and in-
clusion in themeta-analyses of this review. This process is reflected
in the PRISMA flow chart (Figure 2). Of the 76 publications as-
sessed, 17 were duplicate publications, resulting in a total of 59
individual trials. Of the 59 studies assessed, 28 were included, 25
excluded, 4 are awaiting classification and 2 trials were ongoing.
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Figure 2. Study flow diagram.
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Included studies
A total of 28 trials met the criteria for inclusion. Twelve studies
were conducted in the USA (Amin 2005; Barnhart 1999; Casson
1998; Dayal 2005; Hirshman 2003; Hirshman 2004; Kratz 2000;
Kritz-Silverstein 2008; Merritt 2012; Mortola 1990; Stanczyk
2009; Stangl 2010), five in Italy (Genazzani 2011; Lasco 2001;
Pluchino 2008; Silvestri 2005; Stomati 1999), four in Canada
(El-Alfy 2010; Labrie 1997; Labrie 2008; Labrie 2009a), one each
in Australia (Panjari 2009), France (Nouveau 2008), India (Gupta
2013), Israel (Bloch 2013), Spain (Gomez-Santos 2011), Sweden
(Forsblad-d’Elia 2009) and Switzerland (Finckh 2005). We were
unable to retrieve the full text of one study (Amin 2005). Attempts
were made to contact all authors of the included studies to obtain
additional data and for clarification.
Participants
A total of 1273 women were randomised in the 28 included stud-
ies. The total study population was 1207 postmenopausal women
and 66 perimenopausal women. All studies but one (Barnhart
1999) included postmenopausal women only. One study included
100 menopausal women after surgery only (Gupta 2013). Over-
all, the age ranged from 36 to 80 years. Women from different
ethnicities were included, but not all studies reported on this. The
most reported group was Caucasian women. A total of 33% of the
studies included healthy menopausal women (for example with-
out serious comorbidity, not using medication). Two studies only
included women with specific comorbidities: Sjögren syndrome
(Forsblad-d’Elia 2009) andfibromyalgia (Finckh 2005). Two stud-
ies included menopausal women with complaints of vaginal dry-
ness, irritation or itching, or dyspareunia (Labrie 2008; Labrie
2009a). Two studies included women with hypoactive sexual de-
sire disorder or low libido (Bloch 2013; Panjari 2009). One study
included women with an increased cardiovascular risk (Silvestri
2005). The remaining studies did not report health status or co-
morbidities of the women who were included.
Study design
Nineteen parallel-designed RCTs and nine crossover-designed
trials (Finckh 2005; Forsblad-d’Elia 2009; Hirshman 2003;
Hirshman 2004; Labrie 1997; Merritt 2012; Mortola 1990;
Silvestri 2005; Stangl 2010) were included in the review. Fifteen
studies were included for (quantitative) meta-analysis.
Interventions
The following comparisons were made in the included studies:
DHEA versus placebo, head-to-head (DHEA versus other active
treatment) comparisons, and DHEA versus no treatment. There
were a total of:
• 23 included trials comparing DHEA versus placebo (Amin
2005; Barnhart 1999; Bloch 2013; Casson 1998; Dayal 2005;
El-Alfy 2010; Finckh 2005; Forsblad-d’Elia 2009;
Gomez-Santos 2011; Hirshman 2003; Hirshman 2004; Kratz
2000; Kritz-Silverstein 2008; Labrie 1997; Labrie 2008; Labrie
2009a; Lasco 2001; Merritt 2012; Mortola 1990; Nouveau
2008; Panjari 2009; Stanczyk 2009; Stangl 2010);
• six included trials comparing DHEA versus HT (Dayal
2005; Genazzani 2011; Gupta 2013; Pluchino 2008; Silvestri
2005; Stomati 1999). HT included estrogen therapy (ET);
conjugated equine estrogen (Dayal 2005; Gupta 2013);
transdermal estradiol alone (Stomati 1999); transdermal
estradiol plus oral progesterone (ET + P) (Pluchino 2008) or oral
estradiol plus dihydrogesterone (ET + P) (Genazzani 2011);
• three trials compared DHEA versus tibolone (a synthetic
steroid hormone with estrogen and androgens as metabolites)
(Genazzani 2011; Gupta 2013; Silvestri 2005);
• one trial compared DHEA versus no treatment (Gupta
2013).
Routes of administration
• A total of 24 trials used oral administration of DHEA
(Amin 2005; Barnhart 1999; Bloch 2013; Casson 1998; Dayal
2005; Finckh 2005; Forsblad-d’Elia 2009; Genazzani 2011;
Gomez-Santos 2011; Gupta 2013; Hirshman 2003; Hirshman
2004; Kratz 2000; Kritz-Silverstein 2008; Lasco 2001; Merritt
2012; Mortola 1990; Panjari 2009; Pluchino 2008; Silvestri
2005; Stanczyk 2009; Stangl 2010; Stomati 1999).
Daily doses for oral administration of DHEA varied between 10
mg and 1600 mg. One trial used a daily dose of 1600 mg; 2 trials
100 mg/day; 12 trials 50 mg/day; 1 trial 40 mg/day; 5 trials 25
mg/day; 2 trials 10 mg/day.
• A total of three trials used skin application for DHEA
(creams) (El-Alfy 2010; Labrie 1997; Nouveau 2008).
• Two trials used intravaginal administration of DHEA
(Labrie 2008; Labrie 2009a).
Outcomes
Primary outcome: effectiveness (quality of life, general
wellbeing)
Fourteen studies reported quality of life or wellbeing. The re-
sults from 11 of these trials could be included in a meta-anal-
ysis (Barnhart 1999; Bloch 2013; Dayal 2005; Finckh 2005;
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Hirshman 2003; Hirshman 2004; Kritz-Silverstein 2008; Labrie
1997; Labrie 2009a; Merritt 2012; Panjari 2009; Stangl 2010);
nine trials reported end scores for quality of life scales after treat-
ment (Bloch 2013; Dayal 2005; Finckh 2005; Hirshman 2003;
Hirshman 2004; Kritz-Silverstein 2008; Merritt 2012; Panjari
2009; Stangl 2010) whereas two studies reported change scores
(difference between baseline and end scores) (Barnhart 1999;
Labrie 2009a). Three trials (Amin 2005; Kratz 2000; Labrie 1997)
investigated quality of life or wellbeing but required additional
data for inclusion in the meta-analysis.
Different questionnaires were used to assess quality of life in-
cluding: Beck Depression Inventory (BDI) (Hirshman 2003;
Hirshman 2004; Kritz-Silverstein 2008; Merritt 2012; Stangl
2010), Symptom Checklist-90 (SCL-90) (Merritt 2012; Stangl
2010), Women’s Health Questionnaire (WHQ) (Dayal 2005),
Psychological General Well-Being Index (PGWBI) (Finckh 2005;
Labrie 2009a; Panjari 2009), Hamilton Depression Rating Score
(HAM-D) (Barnhart 1999), SmithKline BeechamQuality of Life
Self Report Questionnaire (SKQOL) (Barnhart 1999), Life Satis-
faction Inventory-Z (LSI-Z) (Kritz-Silverstein 2008), Short Form
Health Survey (SF-36) (Kritz-Silverstein 2008), Satisfaction With
Life Scale (SWLS) (Kritz-Silverstein 2008), Mental Health In-
ventory (MHI) (Bloch 2013) and Menopause-specific Quality of
Life Questionnaire (MENQOL) (Labrie 2009a; Panjari 2009). If
studies used multiple questionnaires to assess quality of life we
included scores from questionnaires that were validated and used
in most publications (BDI, PGWBI and SCL-90). Where these
questionnaires were not used, we included the scales we judged as
most representative for quality of life.
Primary outcome: adverse effects
A total of 23 studies reported on side effects. Five trials could be
included formeta-analysis; four trials that used oral administration
(Bloch 2013; Finckh 2005; Lasco 2001; Panjari 2009) and one
trial that used intravaginal administration (Nouveau 2008). Other
studies could not be included for meta-analysis for the following
reasons: 10 studies reported that there were no side effects (Casson
1998; Genazzani 2011; Gomez-Santos 2011; Hirshman 2003;
Hirshman 2004; Pluchino 2008; Silvestri 2005; Stanczyk 2009;
Stomati 1999); one study reported there were no significant side
effects (Labrie 2008), and for one study the author confirmed
that there were no significant side effects found (Labrie 2009a);
two studies only reported adverse effects for women discontinuing
the study (Barnhart 1999; El-Alfy 2010), it was unclear whether
there were any (non-significant) side effects reported for these
studies; one study, which had male and female participants, did
not separate side effects by sex and could therefore not be included
(Kritz-Silverstein 2008); only one trial reported adverse effects for
DHEA versus HT and tibolone (Gupta 2013); results from most
crossover trials (Forsblad-d’Elia 2009; Labrie 1997;Mortola 1990)
could not be included due to lack of data (no combined statistical
tests were done for adverse effects). Attempts were made to contact
all authors to request additional data.
Adverse effects that were reported for DHEA treatment but could
not be included for meta-analysis due to lack of information, as
described above, were as follows:
acne (Labrie 1997), hirsutism (Forsblad-d’Elia 2009; Labrie 1997;
Mortola 1990), contact dermatitis (El-Alfy 2010), parasthesia
and numbness of upper extremity (Barnhart 1999), depressive-
ness (Forsblad-d’Elia 2009), calf cramps (Forsblad-d’Elia 2009),
increase in nightly dreams (Forsblad-d’Elia 2009) and dizziness
(Forsblad-d’Elia 2009).
Secondary outcome: menopausal symptoms
Five studies investigated the effect of the intervention on
menopausal symptoms (Barnhart 1999; Dayal 2005; Genazzani
2011; Gupta 2013; Stomati 1999). Five studies reported contin-
uous outcomes using scales to assess menopausal symptoms, three
studies reported end scores after treatment and could be com-
bined for meta-analysis. Scales used were: Green Climacteric Scale
(Genazzani 2011), Kupperman Index (Stomati 1999) and an el-
ement of the Woman’s Health Questionnaire (Dayal 2005). Two
studies could not be included for meta-analysis because one study
reported change scores (Barnhart 1999) and the other study re-
ported dichotomous outcomes (Gupta 2013).
Secondary outcome: sexual function
A total of eight studies investigated sexual function as an out-
come (Bloch 2013; Dayal 2005; Finckh 2005; Genazzani 2011;
Kritz-Silverstein 2008; Labrie 2009a; Mortola 1990; Panjari
2009). Six studies reported end scores after treatment whereas one
study reported change scores (Barnhart 1999) and could there-
fore not be included in this meta-analysis. Different parameters
were used to assess sexual function including: the McCoy Female
Sexuality Score (MFSQ), Female Sexual Function Index (FSFI),
Derogatis Interview for Sexual Functioning (DISF), Sabbatsberg
Sexual Self-rating Scoring (SSS) and Abbreviated Sexual Function
Questionnaire (ASFQ). The most used questionnaires were the
MFSQ and FSFI. One study stated that no changes in sexual drive
had been reported but did not use a tool to quantify sexual drive
(Mortola 1990). Most studies utilised questionnaires with a total
score to represent sexual function as a whole as opposed to splitting
up the various elements such as libido, dyspareunia etc. Where
studies did provide scores for the separate elements of sexual func-
tion, libido was chosen as the function to represent sexual func-
tion. There were not enough data from the studies to undertake
meaningful subanalyses of the various elements of sexual function.
Excluded studies
We excluded 25 studies: 8 studies were excluded because theywere
non-randomised controlled trials (Buster 2009; Chassany 2000;
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Labrie 2013; Ott 2014; Rodrigo Pegado 2012; Stoll 1999; Yasui
2012; Zouboulis 2012); 1 study was quasi-randomised (Carranza-
Lira 2002); 7 studies were excluded because the study population
did not meet the criteria for inclusion in this review (women were
premenopausal) (Barton 2006; Hartkamp 2004; Kamath 1998;
Lovas 2003; Sanchez-Guerrero 2008; Stein 2011; Virkki 2010);
1 study because the treatment duration was less than a week (
Hackbert 2002); 8 studies because of different study purposes,
7 of these studies were aimed at pharmacokinetics (Bates 1995;
Buster 1992; Calvo 2008; Casson 1993; Casson 1995; Caufriez
2013; Pisarska 1998) and 1was aimed at exercise tolerance (Burger
2003) and they were unlikely to have investigated our outcomes.
We attempted contacting all authors to request additional data.
Unfortunately no additional data became available.
Risk of bias in included studies
See Figure 3 for a summary of the risk of bias for each individual
trial and Figure 4 for a summary of each risk of bias item across
all included trials.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 4. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Sequence generation
Of all 28 included trials, 19 were randomised with a parallel de-
sign and 9 were randomised with a crossover design. Seventeen
trials described their methods of sequence generation, which were
usually computer-generated, randomised block schemes or ran-
dom number tables (Barnhart 1999; Bloch 2013; Casson 1998;
Dayal 2005; Finckh 2005; Forsblad-d’Elia 2009; Genazzani 2011;
Hirshman 2003; Hirshman 2004; Lasco 2001; Merritt 2012;
Nouveau 2008; Panjari 2009; Pluchino 2008; Silvestri 2005;
Stanczyk 2009; Stangl 2010). Eleven trials simply reported the
trial as randomised without a description of the randomisation
method (Amin 2005; El-Alfy 2010; Gomez-Santos 2011; Gupta
2013; Kratz 2000; Kritz-Silverstein 2008; Labrie 1997; Labrie
2008; Labrie 2009a; Mortola 1990; Stomati 1999).
Allocation concealment
Nine trials described their allocation concealment as a sequentially
numbered list kept by the pharmacy, a non-investigator or using
sealed envelopes (Barnhart 1999; Bloch 2013; Dayal 2005; Finckh
2005; Forsblad-d’Elia 2009; Lasco 2001; Panjari 2009; Silvestri
2005; Stanczyk 2009). Nineteen trials did not describe allocation
concealment. Attempts were made to contact these authors to
clarify allocation concealment techniques, unfortunately we were
unable to retrieve the information needed.
Blinding
Blinding of participants and personnel
Fourteen studies (Barnhart 1999; Bloch 2013;Dayal 2005; Finckh
2005; Forsblad-d’Elia 2009; Genazzani 2011; Hirshman 2003;
Hirshman 2004; Lasco 2001; Merritt 2012; Nouveau 2008;
Panjari 2009; Stanczyk 2009; Stangl 2010) described blinding
methods that we graded as low risk. Blinding in these trials was
done by using treatments looking identical in appearance (for ex-
ample identical looking DHEA and placebo capsules or creams).
In some trials personnel were described as blinded as well, but
the majority of the studies did not report on blinding person-
nel. Five studies (Genazzani 2011; Gupta 2013; Labrie 1997;
Pluchino 2008; Stomati 1999) were graded as high risk for bias
as they were not blinded. These trials compared different active
treatments that were applied differently (for example transdermal
patches versus oral capsules) or had different appearances. Nine
studies (Amin 2005; El-Alfy 2010; Gomez-Santos 2011; Kratz
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2000; Kritz-Silverstein 2008; Labrie 2008; Labrie 2009a; Mortola
1990; Silvestri 2005) did not describe their blinding process and
were therefore graded as at unclear risk of bias.
Blinding of outcome assessments
If blinding was unlikely to have been broken for participants it
was unlikely that the outcomes were influenced as the outcomes
were generally done by self-assessment, for all outcomes. If a trial
was not blinded it was likely that this may have influenced the
outcomes. Therefore trials that did not use blinding were graded
as high risk of bias for blinding. We judged the remaining trials as
unclear as it was unclear whether blinding was done or was likely
to have been broken.
Incomplete outcome data
Ten studies analysed all or most women who were randomised
(> 95%) and we judged them to be at low risk of bias (Barnhart
1999; Bloch 2013; Finckh 2005; Forsblad-d’Elia 2009; Genazzani
2011; Hirshman 2004; Labrie 2009a; Lasco 2001; Panjari 2009;
Pluchino 2008). Eighteen studies did not provide data on how
many women completed the trial and were included for analysis
and they were therefore graded as unclear.
Selective reporting
An official protocol was only available for one study, which re-
ported all outcomes described as in the protocol (Bloch 2013).
Two studies (Dayal 2005; Stangl 2010) did not report on one out-
come each (daily symptom rates, SCL-90 scores) that were men-
tioned in their methods sections, but there was availability for
other outcomes that were included and therefore overall bias was
graded as unclear. For the remaining studies the official protocols
were not found or retrieved but no missing data were found com-
paring outcomes measured in the methods sections and the results
sections, we judged these studies as unclear. One study did not
report the outcomes described in their study methods and had no
other data available for meta-analysis and was therefore graded as
high risk of bias (Gomez-Santos 2011).
Other potential sources of bias
In one study no descriptions of randomisation, allocation, blind-
ing and attrition were reported and due to a difference in baseline
scores the end scores were not reliable for both quality of life and
sexual function. Due to this combination of factors the risk of bias
was deemed high (Kritz-Silverstein 2008). We found no potential
sources of within-study bias in the remaining studies.
Effects of interventions
See: Summary of findings for the main comparison DHEA
compared to control (placebo or no treatment) for women in
the peri- or postmenopausal phase; Summary of findings 2
Oral DHEA versus control subgrouped by differing routes of
administration for women in the peri- or postmenopausal phase;
Summary of findings 3DHEA versus HT for women in the peri-
or postmenopausal phase
1. DHEA versus control
1.1 Quality of life (QoL): DHEA versus control (placebo or
no treatment) (end scores)
DHEA did not significantly improve quality of life or wellbeing
end scores compared to placebo (SMD -0.04, 95% CI -0.20 to
0.13, P = 0.67, 9 studies, 402 women (247 from parallel and 155
from crossover trials), I² = 67%) (Analysis 1.1). There were no
studies that compared DHEA to no treatment for quality of life
or wellbeing.
1.2 Quality of life (QoL): DHEA versus control (placebo or
no treatment) (end scores) sensitivity analysis
As the I² value was greater than 50%, we repeated the analysis
but this time we restricted eligibility to studies without a high risk
of bias (SMD 0.16, 95% CI -0.03 to 0.34, P = 0.10, 8 studies,
287 women (132 from parallel and 155 from crossover trials), I² =
0%, moderate quality evidence) (Analysis 1.2; Figure 5). No large
differences in treatment effect were found after conducting the
sensitivity analysis. The heterogeneity observed in 1.1 was found
to be caused by one study (Kritz-Silverstein 2008). This study
showed imbalanced baseline scores and did not report information
on the randomisation technique, allocation, blinding and attrition
and was therefore graded as high risk of bias. We judged the end
scores of this study to be unreliable as they did not represent the
effect of the treatment due to the imbalanced baseline scores for
quality of life. Therefore, we chose to present the result of the
sensitivity analysis as the main result.
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Figure 5. Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.2
Sensitivity analysis QoL and wellbeing (end scores).
The findings from two studies that could not be included formeta-
analysis due to lack of data (no scores available) agreed with the
results above (Kratz 2000; Labrie 1997). One other study that
lacked data for inclusion and only had an abstract available (Amin
2005) reported a slight decrease of quality of life in the placebo
group compared to DHEA treatment.
1.3 and 1.4 Quality of life (QoL): DHEA versus control -
subgrouped based on low libido or hypoactive sexual desire
disorder (HSDD) and treatment duration
See ’overall subgroups’.
1.5 Quality of life (QoL): DHEA versus control (placebo or
no treatment) (change scores)
Two studies reported change scores (difference between baseline
and end scores) (Barnhart 1999; Labrie 2009a). These could not
be pooled due to a high level of heterogeneity (I² = 94%). Sensitiv-
ity analysis did not change this. Heterogeneity may be explained
by route of administration. One study administered DHEA orally
(Labrie 2009a) whereas the other study used intravaginal applica-
tion (see Analysis 2.1).
1.6 Adverse effects: DHEA versus control (placebo or no
treatment)
Nine studies reported therewere no side effects found at all (Casson
1998; Genazzani 2011; Gomez-Santos 2011; Hirshman 2003;
Hirshman 2004; Pluchino 2008; Silvestri 2005; Stanczyk 2009;
Stomati 1999). For one study comparing DHEA with placebo
(Labrie 2008) the author confirmed there were no significant side
effects found, but it was unclear whether there were any minor
adverse effects. There were no studies that compared DHEA to
no treatment.
The results for androgenic side effects could only be pooled for
acne and androgenic side effects (Bloch 2013; Finckh 2005; Lasco
2001; Nouveau 2008; Panjari 2009). The results showed evidence
of an associationwith androgenic side effects (mainly acne) in 15%
of the women on DHEA versus < 3% of women on placebo (OR
3.77, 95% CI 1.36 to 10.40, P = 0.01, 5 studies, 376 women,
I² = 10%, moderate quality evidence). One study (Panjari 2009)
reported on hirsutism as an androgenic side effect but was included
for acne already. Therefore, this study could not be pooled for
hirsutism as well due to risk of double counting participants.
1.6.1. Androgenic side effects: DHEA versus control (placebo
or no treatment)
Due to lack of data we could not combine hirsutism, acne and a
greasy skin into overall ’androgenic side effects’ for meta-analysis.
Only one study (Finckh 2005) reported androgenic side effects
as a total (including acne, greasy skin and hirsutism). Therefore
a meta-analysis could not be conducted. This study showed an
association between androgenic side effects andDHEA treatment.
1.6.2. Acne: DHEA versus control (placebo or no treatment)
There were no significant differences found in the frequency of
acne between DHEA and placebo (OR 2.26, 95% CI 0.56 to
9.02, P = 0.25, 4 studies, 158 women, I² = 0%, moderate quality
evidence) (Analysis 1.6; Figure 6). Two studies (Forsblad-d’Elia
2009; Labrie 1997) reported on acne as a side effect of DHEA
treatment. For one study it was unclear whether this adverse effect
was investigated for placebo as well (Labrie 1997) and the other
study was a crossover trial which had no data available for paired
tests on adverse effects (Forsblad-d’Elia 2009).
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Figure 6. Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.6 Side
effects.
1.6.3. Flushes: DHEA versus control (placebo or no treatment)
Ameta-analysis could not be conducted as only one study reported
sufficient data for flushes as a side effect (Bloch 2013). This study
didnot showan association betweenflushes andDHEA treatment.
Data could not be pooled with other adverse effects due to the risk
of double counting participants.
1.6.4. Hirsutism: DHEA versus control (placebo or no
treatment)
A meta-analysis could not be conducted because only one study
reported sufficient data for hirsutism as a side effect (Panjari 2009).
This study did not show an association between hirsutism and
DHEA treatment (OR 4.89, 95% CI 0.23 to 104.76). Data could
not be pooled with other adverse effects due to the risk of double
counting participants.
1.7 Adverse effects: DHEA versus control - acne subgrouped
based on study duration
See ’subgroups overall’.
1.8 Menopausal symptoms: DHEA versus control (placebo
or no treatment) (continuous)
Insufficient data were available to conduct a meta-analysis for
DHEA versus placebo (Analysis 1.8). Two studies reported
menopausal symptoms as a continuous outcome, one study (in-
cluding 17 postmenopausal women) reported end scores (Dayal
2005) whereas the other study (including 66 perimenopausal
women) reported change scores (Barnhart 1999). Both studies
showed no decrease in menopausal symptoms for DHEA.
1.9 Menopausal symptoms: DHEA versus control (placebo
or no treatment) (dichotomous)
Only one study (Gupta 2013) compared DHEA versus no treat-
ment in 50 menopausal women after surgery, therefore a meta-
analysis could not be conducted. This trial showed a decrease in
menopausal symptoms, for tiredness, night sweats and loss of li-
bido. Other menopausal symptoms reported (hot flushes, insom-
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nia, depression, vaginal dryness and pruritis vulvae) did not differ
for theDHEA treatment and no treatment groups. This study was
not blinded and this may have influenced the outcome.
1.10 Sexual function: DHEA versus control (placebo or no
treatment)
DHEA may have improved sexual function (SMD 0.19, 95%
CI -0.01 to 0.40, P = 0.06, 6 studies, 376 women (354 women
from parallel trials and 22 women from crossover trials), I²
= 10%) (Figure 7). However, one trial including 115 post-
menopausal women (Kritz-Silverstein 2008) showed imbalanced
baseline scores and did not report information on the randomisa-
tion technique, allocation, blinding and attrition and was there-
fore graded as at high risk of bias. Therefore, we chose to conduct
a sensitivity analysis.
Figure 7. Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.11
Sexual function (end scores).
1.11 Sexual function: DHEA versus control (placebo or no
treatment) sensitivity analysis
After conducting a post hoc sensitivity analysis excluding one study
with a high risk of bias, DHEA was shown to be significantly
more effective on sexual function compared to placebo (SMD
0.31, 95% CI 0.07 to 0.55, P = 0.01, 5 studies, 261 women (239
women from parallel trials and 22 women from crossover trials),
I² = 0%, moderate quality of evidence) (Figure 8). We judged
the end scores of the excluded study to be unreliable as it did
not represent the effect of the treatment found in this study due
to imbalanced baseline scores for sexual function. Therefore, we
choose to present the results of the sensitivity analysis as the main
results. The reported improvement in sexual functionwasminimal
although significant and may not be clinically significant as, for
example, an SMD of 0.31 would translate to a change of only 2.3
points on the Sabbatsberg-Sexual Self rating (SSS) scale, which
ranges from 0 to 84. No studies investigated DHEA versus no
treatment.
Figure 8. Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.11
Sexual function (end scores) (sensitivity analysis).
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2. Oral versus other routes of administration (e.g.
intravaginal, transdermal patches)
No studies directly compared oral DHEA versus other routes of
administration. Therefore, we chose to compare studies using oral
DHEA versus studies that used different routes of administration
of DHEA.
2.1 Quality of life (QoL): oral DHEA versus control
subgrouped by route of administration (e.g. intravaginal,
transdermal patches)
There were insufficient data available to conduct a meta-analysis
for effectiveness based on route of administration (Analysis 2.1).
Only one trial (including 107 postmenopausal women) that in-
vestigated a different route of administration than oral administra-
tion (intravaginal application) reportedQoL change scores (Labrie
2009a); and only one trial studied oralDHEAand reported change
scores for QoL (Barnhart 1999). The I² value was greater than
50% (94%) therefore these studies could not be pooled for meta-
analysis. Intravaginal administration showed a beneficial effect for
DHEA on QoL, whereas the other study did not show any differ-
ences in treatment effect.
2.2 Adverse effects: oral DHEA versus control subgrouped
by route of administration (e.g. intravaginal DHEA,
transdermal patches)
No evidence was found that acne was associated more with oral
application of DHEA (OR 2.16, 95% CI 0.47 to 9.96, P = 0,90,
3 studies, 136 women, I² = 5%, very low quality of evidence)
than with skin application of DHEA (OR 2.74, 95% CI 0.10 to
74.87, P = 0,90, 1 study, 22 women, very low quality evidence),
with the test for subgroup differences showing Chi² = 0.02 (df =
1, P = 0.90, I² = 0%) (Analysis 2.2). The studies that investigated
intravaginal administration did not report on acne whereas acne
(or other skin effects) was reported in all trials investigating skin
application (El-Alfy 2010; Labrie 1997; Nouveau 2008) and acne
was reported in five more trials investigating oral administration
(Bloch 2013; Finckh 2005; Forsblad-d’Elia 2009; Lasco 2001;
Panjari 2009). Data for different side effects could not be matched
for anoverall analysis because itwas unclear if these side effectswere
reported in the same or different participants. This information
was needed to create a proper analysis.
2.3 Menopausal symptoms: oral DHEA versus control
subgrouped by route of administration (e.g. intravaginal
DHEA, transdermal patches)
There were no trials using other routes of administration that
investigated menopausal symptoms as an outcome.
2.4 Sexual function: oral DHEA versus control subgrouped
by route of administration (e.g. intravaginal DHEA,
transdermal patches)
No significant differences were found between studies looking at
oral administration (SMD0.11, 95%CI -0.13 to 0.35, P = 0.36, 5
studies, 340 women, I² = 0) and a study using intravaginal DHEA
(SMD 0.42, 95% CI 0.03 to 0.81, 1 study, 218 women) with the
test for subgroup differences showing Chi² = 1.77 (df = 1, P =
0.18, I² = 43.4%) (Analysis 2.4). One trial including 115 post-
menopausal women (Kritz-Silverstein 2008) reported imbalanced
baseline scores and was therefore graded as high risk of bias. There-
fore, we repeated the analysis but this time without studies with
a high risk of bias. The results from the sensitivity analysis also
revealed no evidence for differences between oral administration
and intravaginal application of DHEA on sexual function (SMD
0.31, 95% CI 0.07 to 0.55, P = 0.88, 5 studies, 261 women (of
which 107 received intravaginal DHEA or placebo capsules, 239
women were from parallel trials and 22 women from crossover
trials), I² = 0%).
3. DHEA versus hormone therapy (HT) (estrogen and
progesterone in combination and separately, androgen
therapy or tibolone)
3.1 Quality of life (QoL): DHEA versus hormone therapy
(HT) (estrogen and progesterone in combination and
separately, androgen therapy or tibolone)
Only one study reported results of DHEA versus estrogen (Dayal
2005). Therefore a meta-analysis could not be conducted. This
study found no significant difference between treatment effects of
DHEA compared to HT on QoL.
There were no trials that compared DHEA to a different form of
HT for QoL or wellbeing.
3.2 Adverse effects: DHEA versus hormone therapy (HT)
(dichotomous)
See 3.4.
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3.3 Menopausal symptoms: DHEA versus hormone therapy
(HT)
It was unclear whether DHEA differed from HT in effects on
menopausal symptoms. Two studies were included for the meta-
analysis of estrogen therapy (ET) (Genazzani 2011; Stomati 1999).
The I² value was greater than 50% (74%) therefore these studies
could not be pooled for meta-analysis (Analysis 3.3). One study
showed a small beneficial effect on menopausal symptoms for HT
(Stomati 1999) whereas the other showed a more beneficial effect
for DHEA (Genazzani 2011).
One study that investigated dichotomous outcomes (type and fre-
quency of menopausal symptoms) and could therefore not be in-
cluded in the meta-analysis showed no significant differences in
frequency of various menopausal symptoms between treatments
(Gupta 2013). One trial showed no difference in frequency of
menopausal symptoms between treatments (Gupta 2013). One
study (Genazzani 2011) including 24 postmenopausal women in-
vestigated continuous outcomes and showed a slightly beneficial
effect for DHEA.
3.4 Sexual function: DHEA versus HT
DHEA did not significantly improve sexual function compared to
HT.Two trials (Dayal 2005;Genazzani 2011) compared the effects
of DHEA and HT on sexual function. There was no significant
difference found between these treatments in these two trials (MD
1.26, 95% CI -0.21 to 2.73, P = 0.09, 2 studies, 41 women, I² =
0%) (Analysis 3.4).
Only one trial investigated DHEA versus tibolone (Genazzani
2011). This trial included 24 postmenopausal women and re-
ported a beneficial effect for DHEA compared to tibolone for im-
provement of sexual function.
4. Adverse effects: DHEA versus HT (dichotomous)
Only one study (Gupta 2013) that included menopausal women
after surgery (n = 25 received DHEA, n = 25 received conjugated
equine estrogen (CEE) as ET, n = 25 received tibolone) inves-
tigated this outcome and therefore a meta-analysis could not be
conducted. This study showed an increase in reported acne and
hair loss with DHEA compared to ET.
The same study (Gupta 2013) investigatedDHEAversus tibolone,
but other studies had investigated this comparison for adverse
effects only and a meta-analysis could not be conducted. This
study showed little evidence on adverse effects associated with any
of the treatments. The study reportedmore acne and hair loss with
DHEA compared to tibolone treatment.
5. DHEA versus any other medical treatment (e.g.
antidepressants or clonidine)
No trials were found for this comparison on any of following out-
comes: QoL or wellbeing, adverse effects, menopausal symptoms
or sexual function.
6. DHEA versus any other non-medical treatment (e.g. non-
medical therapies such as acupuncture or complementary
therapies)
No trials were found for this comparison on any of following out-
comes: QoL or wellbeing, adverse effects, menopausal symptoms
or sexual function.
Overall subgroups
There were no or insufficient data available to create subgroups for
BMI, menopausal status, younger females, inflammatory disease
and breast cancer patients. Trials that were conducted measuring
low libido or HSDD could not be pooled due to high hetero-
geneity (I² = 67%). The heterogeneity was caused by one study
with imbalanced baseline scores and a high risk of bias overall
(Kritz-Silverstein 2008). Therefore, we repeated the analysis but
this time without such studies with high risk of bias. This analysis
showed no differences in outcomes for any comparison. Subgroup
analyses that were conducted for treatment duration did not show
any differences in the outcomes for any comparison.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Oral DHEA versus control subgrouped by routes of administration for women in the peri- or postmenopausal phase* * *
Population: Women in the peri- or postmenopausal phase
Settings:
Intervention: DHEA versus placebo (via dif f erent routes of administrat ion)




Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo DHEA
QoL, wellbeing (change
scores) - oral adminis-
tration
The mean QoL, wellbeing in the intervent ion groups was
0.05 standard deviations lower










The mean QoL/ wellbeing in the intervent ion groups was
1.23 standard deviations higher





SMD 1.23 (0.82 to 1.65)
Side effects: acne -
skin application








Side effects: acne -
oral administration








* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; OR: Odds rat io












































































































GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
∗∗∗T herewerenostudiesthatcompareddiff erentroutesof treatmentwithinthestudy.Wehaveseparatedstudiesbasedontheirrouteof administrationandcomparedtheresultsf romthesestudieswitheachother.
1 Downgraded due to no other studies available for comparison of ef fects
2 Downgraded due to lim ited information on randomisat ion, allocat ion and blinding
3 Included subjects with complaints of vaginal dryness, itching, dyspareunia
4Results are controversial (2/ 3 studies favour placebo, whereas 1 favours DHEA)













































































































DHEA versus HT for women in the peri- or postmenopausal phase
Population: Women in the peri- or postmenopausal phase
Settings:
Intervention: DHEA versus HT




Quality of the evidence
(GRADE)
Comments




The mean QoL in the intervent ion groups was
1.63 higher
































DHEA versus ET + P
No studies available
* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
∗∗Astheassumedriskinthecontrolgroupf oracneis0it isimpossibletocalculatethecomparativerisksowehaveassumedariskof 0.05intheplacebogroup.












































































































GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded due to no other studies available for comparison of ef fects













































































































D I S C U S S I O N
Summary of main results
In this review there is no evidence from the pooled sensitivity anal-
ysis of eight studies that DHEA is associated with an improve-
ment in quality of life or wellbeing compared to placebo, hormone
therapy (HT) or no treatment. The quality of the studies in this
analysis that reported quality of life was considered to be moderate
(see summary of findings for the main comparison). DHEA treat-
ment was associated with more androgenic side effects, in 15%
of women (predominantly acne) compared to less than 3% in the
control group. The quality of this evidence was deemed to bemod-
erate. Nine studies reported that no side effects were found.
Limited data were available on the use of DHEA for menopausal
symptoms. The results of studies that reported on menopausal
symptoms were difficult to pool as their outcomes were inconsis-
tently reported (for example as dichotomous or continuous out-
comes, change and end scores) and this may explain the inconsis-
tent results. Two studies reported beneficial effects on menopausal
symptoms for DHEA (versus no treatment and HT), however
one study was unblinded and may therefore have been biased.
More research is needed to see whetherDHEA effectively decreases
menopausal symptoms.
The pooled studies reported that sexual function was potentially
improved with DHEA compared to placebo. After conducting a
sensitivity analysis, excluding one trial with a high risk of bias, this
result changed to evidence of slightly improved sexual function
with DHEA compared to placebo. However, treatment to obtain
this slight improvement would not be clinically justified in light of
the possible side effects with this treatment. Even though DHEA
might slightly improve sexual function compared to placebo there
was no evidence that DHEA improved sexual function more than
HT. However, the results for DHEA versus HT were based on just
two trials with small sample sizes and large confidence intervals
and therefore the quality of the evidence was low.
Overall completeness and applicability of
evidence
Of the 28 trials included in this review, 24 trials investigated
DHEA versus control (placebo or no treatment) and 14 pro-
vided data on quality of life or wellbeing. All trials included
postmenopausal women except for one trial that included peri-
menopausal women. The majority found evidence that DHEA
does not improve quality of life. This level of evidence was judged
to be moderate. No clear associations were found for any side ef-
fects, however the data for side effects were limited. In order to
investigate the effects of DHEA and the risk of developing breast
cancer, follow-up should be for at least five years after the time of
daily intake of DHEA.
The evidence from this review showed that DHEA did improve
sexual function. However the trials were small or moderate in size
and therefore more research is needed to investigate this outcome
as the evidence might change. Different questionnaires were used
to assess quality of life, menopausal symptoms and sexual func-
tion; in some cases these were assessed as part of a wider evalua-
tion. Where studies did provide scores for the separate elements
of sexual function, libido was chosen as the function to represent
this outcome.
Three different routes of administration were reported, oral ad-
ministration, intravaginal and skin application. The majority of
the trials used oral administration of DHEA. There were not
enough data available to investigate any differences in treatment
effects for quality of life and menopausal symptoms. There were
no studies that directly compared the different routes of adminis-
tration of DHEA. Therefore we have separated the studies based
on the route of administration and pooled these results to see if
there were any differences between the different routes. No dif-
ferences were found between oral administration and intravaginal
application for sexual function. However only one study reported
this outcome using intravaginal application, therefore the quality
of the evidence is low. No differences were found for acne as an
adverse effect. Again, the data were limited and the evidence is
graded low.
Five out of 28 trials investigated DHEA versus HT. Not enough
data were available to assess the comparative effect on quality of
life. No evidence was found that DHEA improves sexual function
compared to HT. Only two small trials were included and the
quality of the evidence was low. Further research is needed to
investigate this outcome. For menopausal symptoms, we could
not pool any data and further research is needed. There were no
studies for inclusion that compared DHEA to any other medical
treatments or non-medical treatments.
Quality of the evidence
The overall quality of the evidence for most outcomes was moder-
ate or low. We downgraded the quality of the evidence to moder-
ate for the main outcomes, mainly due to risk of bias and impre-
cision (Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3). Not all trials described
their randomisation technique or methods used to conceal alloca-
tion. Overall, study sizes were small and confidence intervals var-
ied from medium to wide. We were unable to quantify the effect
of publication bias due to the small numbers of studies for any
one outcome. It is possible that studies investigated our outcomes
but found no treatment effect and therefore did not publish their
findings.
Potential biases in the review process
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If studies had a pharmacological intervention and did not report
our outcomes we attempted to contact the authors for additional
information. In cases where these attempts were unsuccessful, we
judged these studies as either likely or unlikely to have investigated
our outcomes and excluded them if theywere judged to be unlikely
to have investigated the outcomes. This might have introduced
a slight bias in the study selection. Changes to the protocol have
been made (please see Differences between protocol and review).
None of the changes were made as a result of the findings of the
included studies but were made to improve the structure of the
review.
Agreements and disagreements with other
studies or reviews
No evidence was found for improvement of quality of life in
menopausal women. These findings are in agreement with find-
ings from one other systematic review (Grimley Evans 2006) and
one literature review (Panjari 2010). We found that androgenic
side effects (mainly acne) were associated with DHEA. DHEA
was reported to be associated with androgenic side effects in other
descriptive reviews as well (Cameron 2005; Kroboth 1999; Panjari
2010). The effects of DHEA on menopausal symptoms were con-
flicting, and little literature is available on DHEA treatment for
menopausal symptoms. One literature review stated that DHEA
did not affect perimenopausal symptoms (Cameron 2005). Thus
far it is still unclear whether DHEA may have a beneficial effect
on menopausal symptoms. Evidence for a slight beneficial effect
of DHEA on sexual function was found in menopausal women,
whereas other descriptive reviews reported little or no evidence of
this (Buvat 2003;Cameron2005; Panjari 2010; Sparke2002). The
studies included in our review were consistent overall in their find-
ings, however the studies were small and more research is needed
to investigate whether DHEA does truly improve sexual function.
Publication bias may have played a part in causing these results as
there may be studies that did not find an improvement in sexual
function and have not published their findings.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results of this review are mainly based on the effects of DHEA
inpostmenopausal women.DHEAwas associatedwith a beneficial
effect on sexual function compared with placebo, however this was
based on a sensitivity analysis after one study with a high risk of
bias was excluded and the quality of evidence is moderate. Effects
of DHEA on peri- and postmenopausal symptoms are unclear as
the reported results were inconsistent. No evidence was found for
improvement of quality of life usingDHEA.No serious side effects
have been reported thus far with daily use of DHEA dosages up
to 1600 mg/day (90% of the studies administered a daily dose of
≤ 50mg/day) with a maximum treatment duration of one year.
However, DHEA was found to be associated with androgenic side
effects, compared to placebo and HT, of which acne was the most
commonly reported.
Implications for research
DHEA treatment does not have a beneficial effect onquality of life.
Even though the data have been limited by small studies, the results
for quality of life have been consistent overall. Further research into
the effects ofDHEAonmenopausal symptoms is desirable as there
were limited data available to evaluate whether DHEA treatment
could decrease menopausal symptoms. To evaluate the effects of
DHEA on sexual function in menopausal women further research
is desirable as the results of this review have shown that there is
evidence for beneficial effects in sexual function for women using
DHEA treatment but the results are limited by small sample sizes
and few studies. New trials should use adequate randomisation
and allocation techniques and should be blinded (double-blinding
preferred).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Amin 2005
Methods Design: Randomised, controlled, parallel trial
Country: USA
Participants Study population: N = 22 postmenopausal women with low endogenous DHEA-S levels
(DHEA N = 11, control N = 11)
Exclusion: smokers and use of HRT
Interventions 1. Oral micronized DHEA 40 mg
2. Placebo
Treatment duration: daily for 1 year
Outcomes Cognitive or psychological function (using LSI-A, among other assessments)
Notes HRT = hormone replacement therapy
LSI-A = Life Satisfaction Index-A
Only abstract available. No full report found or available. Tried contacting the authors,
unsuccessfully
The abstract states the following: “in the LSI-A, the placebo group showed a slight
decrease in scores over time when compared to the treatment group (P = 0.04)”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Stated to be ’double-blind’. However also
states “the treatment group was given a 40
mg daily dose of oral micronized DHEA
for one year, with monthly dose titration
by an unblinded investigator to maintain
levels of DHEA-S between 300 and 450
microgram/dL.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if there were any dropouts
Blinding of outcome assessment Unclear risk Outcomes may have been influenced if
blinding was broken
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Selective reporting (reporting bias) Unclear risk No full text nor official protocol available
Other bias Unclear risk Unclear
Barnhart 1999
Methods Design: single centre, randomised, controlled, parallel trial
Country: USA
Participants Study population: N = 66 perimenopausal women (DHEA N = 33, control N = 33)
Age: 48.8 ± 2 (DHEA) and 48.3 ± 3 (control) (overall age ranged between 45 and 55
years)
Race: 82% Caucasian, 15% African American, and 2% Asian
Inclusion: perimenopausal women with symptoms of fatigue, lack of energy, anxiety,
tension, irritability, depression, insomnia, forgetfulness, concentration difficulties, de-
creased libido, or global reports of a decreased sense of wellbeing
Exclusion: contra-indication to hormonal replacement therapy; exposure to an injectable
or implantable sex steroid within 6 months (including estrogen replacement or DHEA
supplementation) or a systemic steroid within 90 days of treatment; used antidepressants
or antianxiolytics, or both; current diagnosis of major psychiatric disorder, diabetes
mellitus, hypercholesterolemia or cardiovascular disease; abnormal renal or liver function
Interventions 1. Oral DHEA 50 mg
2. Identical placebo
Treatment duration: daily for 3 months
Outcomes Serum endocrine profiles, lipid parameters, Quality of Life (e.g. Ham-D and SKQOL),
perimenopausal symptoms, adverse effects
Notes Age is expressed as mean ± SD
Ham-D = Hamilton Depression Rating Scale
SKQOL = SmithKline Beecham Quality of Life Self Report Questionnaire
Three women discontinued the study because of adverse events: one developed a rash,
one complained of abdominal pain and fatigue (both randomised to placebo) and one
reported paresthesia and numbness of an upper extremity (randomized toDHEA). Three
additional women withdrew consent during the study period
Intention-to-treat analysis of all 66 women was conducted using the last available data
carried to the end of the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Retrieved after contacting authors: “ran-
dom number generation conducted by in-
vestigational pharmacy“
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Allocation concealment (selection bias) Low risk Retrieved after contacting authors: ”block
randomization conducted by investiga-
tional pharmacy.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “To receive a daily capsule of 50mgDHEA,
or identical placebo capsule for 3 months”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Because dropout was small (9%) and bal-
anced, the primary analysis was conducted
for those who completed the trial”
Blinding of outcome assessment Low risk “perimenopausal symptoms were evalu-
ated by both validated subject and clini-
cian-administered assessments”
Selective reporting (reporting bias) Unclear risk Official protocol not available or found
Other bias Unclear risk Funding by Bristol Myer Squibb Clinical
Research Award and a grant from the Uni-
versity of Pennsylvania Research Founda-
ton, Delaware affiliate of the American
Heart Association
Bloch 2013
Methods Design: single centre, randomised, controlled, parallel study
Country: Israel
Participants Study population: N = 48, postmenopausal women (n = 27 of which DHEA (n = 14)
and control (n = 13)) and men (n = 21)
Stratification was done for postmenopausal women. The following information was
based on postmenopausal women
Age: 52.2 ± 6.3 (control) and 55.8 ± 3.7 years (DHEA)
Inclusion: age between 45 and 65 years. All women were postmenopausal (at least one
year of amenorrhoea); meet DSM-IVHSDD (hypo-active sexual desire disorder) criteria
by the Structured Clinical Interview for DSM-IV Axis I Disorders
Exclusion: any psychiatric diagnoses of psychosis, currentmajor depression or dysthymia;
drug or alcohol abuse; major systemic illness or hypogonadism; antidepressant, hormone
replacement therapy or androgen treatment; breast, ovary or uterine cancer and first
degree breast cancer in women; no failed trial with DHEA
Interventions 1. Oral DHEA 100 mg (50 mg twice a day)
2. Placebo - dummy pills, identical in appearance to the active pills
Treatment duration: daily for 6 weeks
Outcomes Sexual function (using DISF, FSFI), wellbeing (MHI), side effects and hormone serum
levels
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Notes Age and BMI are expressed as mean ± SD
DISF = Derogatis interview for Sexual Functioning
FSFI = Female Sexual Function Index
MHI = Mental Health Inventory
16 women were included in intention-to-treat analysis (13 in each arm), 1 was excluded
because of non-compliancy (1 woman did not complete the full trial, due to lack of
motivation)
Side effects reported at week 6 were: hot flushes (3 women, 2 on DHEA and 1 on
placebo), and acne (1 woman on placebo)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “random patient serial numbers with active
vs placebo ratio of 1:1 were generated and
randomly assigned to eligible patients”
Allocation concealment (selection bias) Low risk Information retrieved after contacting the
author: “All packaging of medication and
randomization was done at the hospital’s
pharmacy and allocation was done by my-
self and a research assistant who then gave
the medication to the treating physician
who was blinded to the treatment condi-
tion.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Both physicians and research assistants
were blinded to the treatment condition”
“The placebo group received dummy pills
daily, identical in appearance to the active
pills, according to the same protocol as the
active group”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data were addressed
Blinding of outcome assessment Low risk “The interviewer and manager of the pa-
tients (LA) is a certified senior gynecologist
and sexual therapist who discussed the di-
agnosis for each case with the psychiatrist
(MB). Both physicians and research assis-
tants were blinded to the treatment condi-
tion.”
Selective reporting (reporting bias) Low risk Study is reg-
istered at clinicaltrials.gov (http://clinical-
trials.gov/show/NCT00916396). All out-
comes have been reported
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Other bias Unclear risk Unclear
Casson 1998
Methods Design: single centre, randomised, placebo-controlled, parallel trial
Country: USA
Participants Study population: n = 13 postmenopausal women
Inclusion: healthy postmenopausal non-smokers with serum DHEAS levels of < 125
µg/dL
Exclusion: the subjects were screened for thyroid or liver disease
Interventions 1. Oral micronized DHEA tablet of 25 mg
2. Identical wax vehicle excipient placebo tablet
Treatment duration: once daily for 6 months
Outcomes Serum steroid levels; growth hormone levels; serum lipoproteins; metabolic, immune
and morphometric indices and safety profile
Notes No detectable side effects were seen
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was performed by a nurse
from a computer-generated random num-
ber table.”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Low risk It states it is ’double blinded’, placebo and
DHEA tablets were identical, however no
further description of blinding personnel,
likely to be blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if there were any dropouts
Blinding of outcome assessment Low risk Blinding unlikely to have been influenced
Selective reporting (reporting bias) Unclear risk Official protocol not found or available
Other bias Unclear risk Unclear
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Methods Design: single centre, randomised, 4-armed parallel trial (included both a head-to-head
and placebo-controlled comparison)
Country: USA
Setting: Univerisity of Pennsylvania Medical Center (UPMC)
Study period: February 1999 through February 2001
Participants Study population: N = 50 (32 randomised) (n = 12 (DHEA), n = 5 (ET), n = 9 (DHEA
+ ET), n = 6 (placebo)
Age: between 44 and 70 years (mean 56.6)
Race: 78% white
Inclusion: study participants were menopausal women, with a history of no menstrual
cycle for at least one year or at least six months of amenorrhea with a documented
follicle-stimulating hormone (FSH) level > 40 mIU/ml. These subjects had no exposure
to hormone therapy (specifically estrogen therapy (ET) or DHEA supplementation) for
at least 60 days prior to enrollment, had a normal Pap smear and mammogram within
the last year, and had normal liver transaminase levels, renal function, total cholesterol,
and triglyceride (TG) levels
Exclusion: women were excluded if they had any contraindication to ET (known or
suspected cancer of the breast, endometrial hyperplasia/carcinoma, undiagnosed vaginal
bleeding, active thromboembolic disorders, or history of cerebrovascular disease, coro-
nary artery disease (CAD), ormyocardial infarction (MI)), a current diagnosis of diabetes
mellitus, uncontrolled hypertension, abnormal liver or renal function, major psychiatric
disorder (major depression, bipolar disorder, psychotic disorder, drug addiction), or any
contraindication to the use of MRI (pacemaker, magnetic aneurysm clip, severe claus-
trophobia)
Interventions 1. Oral DHEA 50 mg
2. Conjugated quine estrogen (CEE) 0.625 mg
3. Oral DHEA 50 mg + CEE 0.625 mg
4. Placebo
treatment duration: daily for 12 weeks
Outcomes Muscle size, strength, quality of life and vasomotor symptoms (using the the Women’s
Health Questionnaire) and lipids
Notes To be able to include the results for quality of life in our meta-analysis, end scores were
calculated based on the percentage change scores that were reported at the end of the trial,
the standard deviation of the baseline measurements was then used for these calculated
end scores as well
Only the DHEA, CEE and placebo group in our meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “subjects were randomized, into four treat-
ment groups using a computerized pro-
gram generating random numbers”
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Allocation concealment (selection bias) Low risk Random number generation conducted by
investigational pharmacy
Blinding (performance bias and detection
bias)
All outcomes
Low risk After contacting author: “Capsules were
constructed by investigational pharmacy
and were identical for active and placebo.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if there were any dropouts. Author
could not provide additional data
Blinding of outcome assessment Low risk Self-assessment, blinding unlikely to have
been broken
Selective reporting (reporting bias) Unclear risk For the duration of the study, patients were
instructed to rate symptoms on the daily
symptom rating (DSR) calendar at home.
The results were not reported. Official pro-
tocol not found or available. Author could
not provide additional data
Other bias Unclear risk Unclear
El-Alfy 2010
Methods Design: randomised, placebo-controlled, parallel trial
Country: Canada
Participants Study population: N = 75 (placebo (n = 15), 0.1% DHEA (n = 15), 0.3% DHEA (n =
15), 1% DHEA (n = 15), 2% (n = 15)
Age: 60 to 65 years
Race or ethnicity: white women
BMI: the body mass index of all women ranged between 18.5 and 29.0 kg/m²
Inclusion: healthy postmenopausal white women. All subjects had a medical history,
complete physical examination, serum biochemistry as well as full blood analysis
Exclusion: none of the women had received any hormone replacement therapy for at
least the last 6 months before the beginning of the study. No subject was under treat-
ment with lipid or glucose lowering agents. There was no active or history of thrombo-
embolic disease, significant metabolic or endocrine disease and no clinically significant
gastrointestinal, liver or gallbladder disease. None of the women suffered from migraine
or diabetes mellitus not controlled by conventional therapy. None had received corticos-
teroid treatment within the last 6 weeks before the beginning of the study or treatment
with b-carotenoid, retinoic acid, hydroquinone or a-hydroxyacid (including inhaled,
topical or oral). None of the women suffered hypertension ≥160 95 mmHg or not
controlled by standard therapy, confirmed clinically significant depression or confirmed
severe psychiatric disturbance. None of the women had received any experimental drug
within the 30 days before the screening visit or any previous treatment with androgens
or anabolic steroids within the 6 months before the screening visit. None had received
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any antidepressant, antipsychotic or analgesic within 30 days before the beginning of the
study. Smoking any number of cigarettes was an exclusion criterion. There was no former
or present narcotic addiction or alcoholism. There was no hepatic or renal impairment
or condition known to affect drug or steroid metabolism
Interventions 1. 0.1% DHEA cream
2. 0.3% DHEA cream
3. 1% DHEA cream
4. 2% DHEA cream
5. 0% DHEA cream (placebo)
Treatment duration: 3.0 mL applied on the face, arms, back of hands, upper chest and
right thigh twice daily for 13 weeks
Outcomes Skin responses, side effects
Notes Reasons for withdrawals reported as:
0.1% DHEA:1 at week 4 (skin problems), 1 week 8 (keratosis)
0.3% DHEA - none
1% DHEA - 5 at week 7 (serum levels DHEA above 11 ng/mL-1)
2%DHEA - 1 at day 6 (contact dermatitis), 1 at week 4 (contact dermatitis), 10 at week
7 (serum levels DHEA above 11 ng/mL-1)
For meta-analysis we will only use the 2% results of the 2% DHEA group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Each subject was randomly assigned to
one of the following five groups: 0%
DHEA (placebo), 01% DHEA, 03%
DHEA, 1%DHEA and 2%DHEA.”Ran-
domisation technique not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Likely that the creams were identical in ap-
pearance, however not described. Does not
state ’blinded’ in report
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reasons for withdrawals are stated
Blinding of outcome assessment Unclear risk If not blinded or blinding was broken it
may have influenced the outcomes
Selective reporting (reporting bias) Unclear risk Official protocol not available or found
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Other bias Unclear risk Funding was provided by Endorecherche
Inc
Finckh 2005
Methods Design: single centre, randomised, placebo-controlled, crossover trial
Country: Switzerland
Recruitment: patients were recruited through the Swiss Association of Fibromyalgic
Patients and the Rheumatology Clinic of University Hospital of Vaud (CHUV)
Participants Study population: N = 52 postmenopausal women
Age: 59.2 ± 8.8 (DHEA), 58.7 ± 9.7 (placebo), range 36 to 83 years
Race: all caucasian
Inclusion: confirmed fibromyalgia by 1990 American College of Rheumatology classi-
fication criteria 21; female gender; postmenopausal status (or bilateral oophorectomy);
and ability to complete questionnaires
Exclusion: current treatment with narcoleptics or steroids; history of sex hormone-re-
sponsive cancer (breast, ovarian, or endometrial cancer); advanced liver, kidney, or heart
disease; history of chronic inflammatory disease (i.e. rheumatoid arthritis, SLE)
Interventions 1. Oral DHEA capsule 50 mg
2. Identical placebo containing mannitol
Treatment duration: daily for 3 months. Washout period for 1 month
Outcomes Quality of life (by using PGWBI), regional pain, sexual function (by using McCoy FSQ
), cognitive function, side effects
Notes Age expressed as mean ± SD
PGWBI = Psychological General Well Being Index
McCoy FSQ = McCoy Female Sexuality Questionnaire
For meta-analysis the scores have been used as they have been analysed in the paper (for
analysis of QoL 47 women were included for DHEA and 45 for placebo and for sexual
function 20 women were included for DHEA and 22 for placebo)
Androgenic side effects were more common with DHEA: 11 patients (25%) complained
of greasy skin, acne, or increased growth of body hair, compared to 2 patients (4%) with
placebo (P = 0.023, McNemar)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “patients were randomized to eitherDHEA
or placebo in balanced blocks of 6 bymeans
of a random number generator”
Allocation concealment (selection bias) Low risk “The medication codes were kept in sealed
envelopes until the end of the study.”
Author confirmed these envelopes were opaque
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Blinding (performance bias and detection
bias)
All outcomes
Low risk “Both patients and investigators were
blinded to the treatment group assign-
ment”
“Study capsules of DHEA 50mg and iden-
tical opaque placebo capsules containing
mannitol were produced and packet by the
hospital’s pharmacy”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data addressed
Blinding of outcome assessment Low risk Blinding unlikely to have been broken -
self-assessed outcomes
Selective reporting (reporting bias) Unclear risk Official protocol not found or available
Other bias Unclear risk Unclear
Forsblad-d’Elia 2009
Methods Design: randomised, placebo-controlled, crossover trial
Country: Sweden
Setting: patients were identified from registers in two rheumatology clinics in Western
Sweden
Participants Study population:N=23postmenopausal women (initialDHEA (n =13), initial placebo
(n = 10)
Age: 60.7 ± 8.6 years
Inclusion: postmenopausal women with primary Sjogren’s syndrome and subnormal
levels of DHEA-S
Exclusion: patients with a history of breast cancer or uterine cancer, previous stroke or
known diathesis for thrombosis, difficult acne, or a significant liver disease and patients
with changes in treatment with disease-modifying antirheumatic drugs (DMARD) or
changes in lowdose glucocorticosteroids taken for Sjogren’s during the previous 3months
were excluded from the trial, as were patients taking more than 10 mg prednisolone per
day
Interventions 1. Oral DHEA 50 mg
2. Placebo
Treatment duration: daily for 4 months, washout period 1 month, crossover
Outcomes Serum levels of DHEA and 12 of its metabolites, sex steroids and disease related variables,
side effects
Notes Author was contacted to retrieve more information on side effects. Two patients experi-
enced adverse events resulting in discontinuation of the study drug: one woman due to
increase in nightly calf cramps during DHEA, and the other to a suspected transitory is-
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chemic attack during placebo. Other reported adverse events during DHEA period were
acne and increase in perspiration, increase in nightly dreams, depressiveness, dizziness
and hirsutism. During placebo period gastric pain and headache
Age is expressed as mean ± SD
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “patients were randomized to eitherDHEA
or placebo in balanced blocks of 6 bymeans
of a random number generator”
Allocation concealment (selection bias) Low risk “The medication codes were kept in sealed
envelopes until the end of the study.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Both patients and investigators were
blinded to the treatment group assign-
ment”
“Study capsules of DHEA 50mg and iden-
tical opaque placebo capsules containing
mannitol were produced and packet by the
hospital’s pharmacy”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data have been addressed
Blinding of outcome assessment Low risk Blinding unlikely to have been broken and
self-administered questionnaires
Selective reporting (reporting bias) Unclear risk Official protocol not found or available
Other bias Unclear risk Study population had subnormal DHEA
levels
Genazzani 2011
Methods Design: multicentre, randomised controlled (head-to-head), parallel trial
Country: Italy
Recruitment: patients referred from the Department of Obstetrics and Gynecology,
University of Pisa and from the Francavilla Fontana Hospital ’D. Camberlingo’
Participants Study population: N = 48 (DHEA (n = 12), estradiol + dihydrogesterone (n = 12),
tibolone (n = 12) and oral vitamin D (n = 12)
Age: between 50 and 60 years (mean age 54.5 ± 3.3 years). Placebo 55.2 ± 2.9, DHEA
53.5 ± 3.8, HRT 54.5 ± 2.9, tibolone 53.8 ± 3.1
Inclusion: healthy postmenopausal women who reported climacteric symptoms. All sub-
jects had natural menopause and were healthy. Natural menopause was defined retro-
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spectively after 12 consecutive months without natural menstrual periods, and age at
menopause was the age at last menstruation.
Exclusion: previous or current endocrine disorders, such as thyroid or adrenal dysfunction
or altered prolactin circulating levels; treatment of cardiovascular diseases, hypertension
or psychiatric disorders; previous or current hormone treatments known to influence
endocrine function; smoking; presence of any kind of pelvic and breast disease
Interventions 1. Oral DHEA 10 mg daily
2. Oral estradiol (1mg) plus dihydrogesterone (5mg) (HRT) (Femoston Conti®, Solvay
Pharma SpA)
3. Oral tibolone tablet (2.5 mg) (Livial®, Schering-Plough SpA)
4. Oral vitamin D (400 IU) plus calcium carbonate (1250 mg) (women refused HRT)
- this group was not randomised and thus not included in our meta-analysis
Outcomes Climacteric symptoms (by using the Green scale) and female sexuality (by using the
MFSQ)
Notes Age expressed as means ± SD
MFSQ = McCoy Female Sexuality Questionnaire
All those patients who enrolled in the study completed the follow up without any adverse
effects
The scores ± SD for climacteric symptoms were estimated from reported figures. For
tibolone the scores were estimated for sexual function from reported figures as well.
Unfortunately we were unable to retrieve the exact scores ± SD from the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization, in three hormone-treated
groups, was made using a computer-gen-
erated block, random-permutation proce-
dure.”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
High risk Not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk “All those patients who enrolled in the
study completed the follow-up, without
any adverse events.”
Blinding of outcome assessment High risk “self-administered questionnaires” but not
blinded
Selective reporting (reporting bias) Unclear risk Official protocol not found or available
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Other bias Unclear risk Received funding from ’Nil’. No conflicts
of interest were declared
Gomez-Santos 2011
Methods Design: randomised, placebo-controlled, parallel trial
Country: Spain
Recruitment: subjects were recruited from the “Health Centre of Espinardo”
Participants Study population: n = 61 postmenopausal women (DHEA (n = 41), control (n = 20))
Age: 52 ± 1 (DHEA) and 51 ± 2 (control)
BMI: 33.08 ± 0.62 (DHEA) and 34.45 ± 1.19 (control)
Inclusion criteria were as follows: overweight women, obesity type I or II and without
changes in their normal diet during treatment. Menopause was defined as the date of
the last menses followed by 12 months of no menses and a follicle-stimulating hormone
level higher than 30 mIU/mL
Exclusion criteria were as follows: women following any special diet, steroid or thyroid
medication, or diagnosed with diabetes mellitus, chronic renal failure, hepatic disease or
cancer
Interventions 1. Oral DHEA-S 100 mg
2. Placebo
Treatment duration: once daily for 3 months
Outcomes Human plasma fatty acid profile in plasma, side effects
Notes “Potential adverse effects were monitored by means of interviews, physical examinations
and standard laboratory tests”. Side effects not reported in results section
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Subjects were randomly divided into two
groups: ‘placebo’ receiving a placebo and
‘treated’ (n = 41, 52 ± 1 y)”
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Stated to be “Double-blind”, but no de-
scription of how blinding done was ob-
tained
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if there were any dropouts
Blinding of outcome assessment Unclear risk Unclear if blinding could have been broken
it may have influenced the outcomes
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Selective reporting (reporting bias) High risk “Potential adverse effects were monitored
by means of interviews, physical examina-
tions and standard laboratory tests”. Unfor-
tunately the results of this monitoring have
not been reported and we were unsuccess-
ful in contacting the authors
Other bias Unclear risk Unclear
Gupta 2013
Methods Design: single centre, randomised, controlled comparative trial
Country: India
Setting: Department of Obstetrics and Gynaecology of SMS Medical College Jaipur
Participants Study population: N = 100 surgically menopausal women (premarin (CEE (n = 25),
DHEA (n = 25), tIbolone (n = 25), no treatment (n = 25)
Inclusion: asymptomatic patients as regards to menopausal symptoms who had under-
gone total abdominal hysterectomy with bilateral salpingo-oophorectomy 3 days earlier
Exclusion: patients with carcinoma endometrium, liver, breast or ovary, endocrine dis-
eases (diabetes, thyroid), cardiovascular, cerebrovascular and peripheral vascular disease,
hypertension, severe renal disease or liver disease, bone metabolic diseases, obesity (BMI
(30), smokers and alcoholics, and with history of thrombophlebitis or immunosuppres-
sive drugs were excluded from the study
Interventions 1. Oral Premarin (CEE 0.625 mg)
2. Tibofem (2.5 mg)
3. Evandra (DHEA 25 mg)
All daily
4. No treatment
Treatment duration: 12 months
Outcomes Menopausal symptoms, lipid variables, bone densitometry, side effects
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation technique unclear. “The
control and cases were allotted to their re-
spective groups randomly”
Allocation concealment (selection bias) Unclear risk Not described
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Blinding (performance bias and detection
bias)
All outcomes
High risk Not blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Stopping rate for HRT was 2 % at 1
month and another 2 % at 6 months” - un-
clear if these subjects were included or ex-
cluded in analysis
Blinding of outcome assessment High risk Self-assessment, but not blinded, likely to
influence the outcomes
Selective reporting (reporting bias) Unclear risk Official protocol not found or available
Other bias Unclear risk Unclear
Hirshman 2003
Methods Design: single centre, randomised, placebo-controlled, crossover trial
Country: USA
Recruitment: all participants were volunteers recruited by newspaper advertisement, and
they were paid USD 100 for their participation
Participants Study population: N = 30 postmenopausal women
Age: 54.3 ± 7.07 (range 39 to 70) years
Race: Caucasian (n = 27), African-American (n = 3)
Inclusion: the participants met the World Health Organization’s criteria for post-
menopausal status of 1 year’s absence of menses or bilateral oophorectomy that preceded
the study by one year
Exclusion: potential participants were excluded from the study if they reported a serious
mental illness (e.g., schizophrenia, depression), a serious physical illness within the last
year (e.g. cardiac arrest), a history of drug or alcohol abuse, or current use of benzodi-
azepines, narcotics, or amphetamines
Interventions 1. Oral DHEA pills of 50 mg (2 pills of 25 mg)
2. Lactose tablets (placebo)
Treatment duration: daily for 4 weeks directly followed by crossover (no washout period)
Outcomes Recognition memory decision process, effect on depression (by measuring BDI), adverse
effects
Notes Age expressed as mean ± SD
BDI = Beck depression inventory. No adverse events were reported
Additional data were requested, unfortunately not obtained
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Information retrieved after contacting au-
thor: “our within participant designs uses
a crossover design; our between participant
designs uses a simple block randomization”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Daily doses of DHEA and placebo con-
sisted of two white pills.”
Information retrieved after contacting au-
thor: “placebo and drug identical in both
studies”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk After contacting author “no attrition due
to side effects in either study”. Unclear if
there were any other withdrawals
Blinding of outcome assessment Low risk Blinding unlikely to have been broken
Selective reporting (reporting bias) Unclear risk Official protocol not found or available
Other bias Unclear risk “All participants were volunteers recruited
by newspaper advertisement, and theywere
paid $100 for their participation”
No washout period
Hirshman 2004
Methods Design: single centre, randomised, placebo-controlled crossover trial
Country: USA
Recruitment: all subjects were volunteers recruited by newspaper advertisement andwere
paid USD 300.00 for their participation
Participants Study population: n = 6 postmenopausal women
Age: 58.5 ± 2.16 (range 53 to 68) years
BMI: 30.2 ± 1.47 (range 26.7 to 33.7)
Inclusion: Participants met theWorld Health Organization’s criteria for postmenopausal
status of 1 year’s absence of menses (four participants) or bilateral oophorectomy that
preceded the study by at least 1 year (two participants). None of the participants were
using hormone replacement therapy. All women enrolled had a normal mammogram
within the prior year and a normal Pap smear within the prior 3 years
Exclusion: Potential participants were excluded from the study if a preenrollment med-
ical evaluation revealed contraindications to DHEA treatment (i.e. personal history of,
or active, breast cancer or other estrogen- dependent neoplasms, acute liver disease,
undiagnosed vaginal bleeding, uncontrolled hypertension, history of clotting disorders,
and history of psychiatric or cognitive disorders). Women whose preenrollment assays
of DHEAS, estradiol, or testosterone were above the normal postmenopausal women’s
range were excluded. Similarly, subjects whose body mass index (BMI) exceeded 35
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were excluded. Current use of a range of substances that influence cognition (e.g. am-
phetamines, benzodiazepines, narcotics, and nicotine) was also grounds for exclusion
Interventions 1. Oral DHEA capsule 50 mg
2. Placebo (consisted of lactose) identical to DHEA capsule
Treatment duration: daily for 4 weeks, 1 week washout, followed by crossover treatment
Outcomes Androgen blood levels, effects on cognition (performance on recognition memory, per-
ceptual identification, digit span memory, visual attentional vigilance)
Notes Age and BMI expressed as mean ± SEM
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Subjects who met the eligibility require-
ments were randomly assigned (in a block-
randomization scheme) to receive DHEA
(placebo) in the first 4-week period and
placebo (DHEA) in the second 4-week pe-
riod”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Low risk “DHEAwas compounded by Belmar Phar-
maceutical (Lakewood, CO). Oral place-
bos consisted of lactose and were presented
in capsules identical to those containing
hormones.” “All investigators and partici-
pants were blind to treatment status.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All datawere addressed. “Fourwomen,who
underwent screening, were not allowed to
participate in the study. The reasons for ex-
clusion of these women were (1) detection
of a pituitary tumor based on preenroll-
ment blood work; (2) detection of psychi-
atric illness based on preenrollment psychi-
atric testing; (3) BMI and hormonal values
that exceeded the selection criteria; and (4)
failure to have a Pap smear in the preceding
3 years.”
Blinding of outcome assessment Low risk Blinding unlikely to have been broken
Selective reporting (reporting bias) Unclear risk Protocol not found or available
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Other bias Unclear risk Unclear
Kratz 2000
Methods Design: single centre, randomised, placebo-controlled, parallel trial
Country: USA
Enrolment: subjects were recruited through the Los Angeles County Women’s Hospital
and through the USC Alzheimer’s Disease Research Center. Nineteen subjects were
recruited through advertisement and word of mouth from the Los Angeles County
Women’s Hospital. One subject was recruited after mailing a letter which described the
study to potential subjects identified from theUSC Alzheimer’s Disease Research Center
(ADRC)
Participants Study population: N = 20 postmenopausal women (n = 11 (DHEA), n = 9 (placebo)
Age: 52.1 ± 4.3 (DHEA), 52.3 ± 5.9 (placebo)
Race: 70% was hispanic (n = 14), 30% caucasian (n = 6)
Inclusion: aged between 46 and 66 years. All subjects received a general physical exami-
nation and a pelvic examination to ensure that they were postmenopausal and in good
health
Exclusion: hormone therapy or suffering from any severe psychopathology
Interventions 1. Oral DHEA 25 mg
2. Placebo
Treatment duration: daily for 6 months
Outcomes Neuropsychological tests (including BDI, SCL-90), hormone assays
Notes Age is expressed as mean ± SD
Lack of data to include in meta-analysis
SCL-90 = Symptom Check List-90
BDI = Beck Depression Index
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States “randomized”. Randomisation tech-
nique is not described
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk States “double-blind”, blinding is not fur-
ther described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if there were any dropouts
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Blinding of outcome assessment Unclear risk If blinding was broken it may have influ-
enced the outcomes
Selective reporting (reporting bias) Unclear risk Official protocol not found or available
Other bias Unclear risk Unclear
Kritz-Silverstein 2008
Methods Design: single centre, randomised, placebo-controlled, parallel trial
Country: USA
Enrolment: between june 2001 and May 2001
Participants Study population: N = 225 (men n = 110, women n = 115 of which n = 57 (DHEA), n
= 58 (placebo)
Study stratified for women. Only information and the results of these women will be
used in our review
Age: 68.9 ± 8.1 (DHEA) and 68.5 ± 6.7 (placebo), range 55 to 85 years
Inclusion: participants were healthy, community dwelling individuals, not selected on
the basis of DHEA level at entry. Non-smokers and not currently using HRT
Interventions 1. Oral DHEA 50 mg
2. Placebo
Treatment duration: daily for 12 months
Outcomes Cognitive function (including Beck Depression Inventory, Life Satisfaction index-Z,
SatisfactionWith Life Scale, SF-36 and Female Sexual Function Index), serum hormone
levels
Notes Age is expressed as mean ± SD
BDI = Beck Depression Inventory
LSI-Z = Life Satisfaction Index-Z
SWLS = Satisfaction With Life Scale
SF- 36 = Medical Outcomes Study 36-item Short Form Survey
FSFI = Female Sexual Function Index
Scores of FSFI and BDI have been used in meta-analysis. Baseline scores for BDI 5.3
± 0.6 (DHEA) versus 4.3 ± 0.6 (placebo) and FSFI 13.3 ± 1.6 (DHEA) versus 16.4 ±
1.6 (placebo) were unbalanced, whereas end scores were improved more in the DHEA
group (4.0 ± 0.6) versus placebo (3.5 ± 0.6) for both outcomes. Unfortunately we do
not have a standard deviation for the ’change scores’ from baseline to end scores, and
end scores alone not representative for this study. Therefore this study has been excluded
for sensitivity analysis
Study reports adverse effects, but unfortunately it does not report adverse effects for men
and women separately therefore we were unable to include these adverse effects in our
review
Risk of bias
53Dehydroepiandrosterone for women in the peri- or postmenopausal phase (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kritz-Silverstein 2008 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation technique unknown. Base-
linemeasurements are unbalanced between
both treatment groups
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk States double-blind, however blinding is
not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if there were any dropouts
Blinding of outcome assessment Unclear risk If blinding was broken it may have influ-
enced the outcomes
Selective reporting (reporting bias) Unclear risk Official protocol not found or available
Other bias High risk Baseline measurements are unbalanced be-
tween both treatment groups for both qual-
ity of life and sexual function outcomes
which caused the end scores not to be rep-
resentative
“The editor in chief has reviewed the con-
flict of interest checklist provided by the
authors and has determined that the au-
thors have no financial or any other kind
of personal conflicts with this manuscript.
Funding was received from National Insti-
tutes of Aging Grant AG018339 and Na-
tional Center for Research Resources Grant
M01RR 00827”
Labrie 1997
Methods Design: randomised, placebo-controlled, crossover trial
Country: Canada
Participants Study population: n = 14 healthy postmenopausal women
Age: 60 to 70 years (mean 63.7 ± 0.76)
Inclusion: non-smokers. All women had a medical history, complete physical examina-
tion, and serum biochemistry profile including lipids, complete blood count, urinalysis,
and detailed serum hormone determinations during the screening phase of the protocol
Exclusion: HRT or medication known to act on bone metabolism during the previous
5 years. Suffering from an endocrine disorder. Taking lipid- or glucose-lowering agents
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Interventions 1. DHEA 10% cream
2. Placebo
Treatment duration: placebo treatment for 6 months preceding or following 12 months
DHEA therapy
Outcomes Secondary effects (adverse effects, wellbeing), bone density, vaginal cytology, endometrial
histology, sebum secretion, serum hormone-binding globulin (HBG)
Notes Paper states there were two women with an increase in facial hair growth on the upper lip,
and two other women developed slight acne during treatment. Wellbeing and increase
in energy were reported in 80% of women. Unclear if this was measured in all women
or only in the active treatment group. Not enough data to include in quantative meta-
analysis. Author was contacted, unfortunately we were unable to retrieve additional data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Author of study assumes it was “properly
randomized”, however randomisation not
described
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
High risk Not blinded, treatment durations of
placebo and DHEA are not equal
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if there were any dropouts
Blinding of outcome assessment High risk Not blinded, outcomes may have been in-
fluenced
Selective reporting (reporting bias) Unclear risk Offical protocol not available or found
Other bias Unclear risk Unclear
Labrie 2008
Methods Design: single centre, randomised, placebo-controlled trial
Country: Canada
Participants Study population: n = 40 postmenopausal women (n = 10 (DHEA1.8%), n = 10 (DHEA
1.0%), n = 10 (DHEA 0.5%), n = 10 (DHEA 0.0%)
Age: between 40 and 75 years
BMI: between 18.5 and 29.9 kg/m²
Inclusion: no menses for≥ 1 year or; FSH levels≥ 40 IU/L (within 60 days prior to day
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1) in women with no menses≥ 6 but < 12 months or hysterectomized women who were
premenopausal at the time of hysterectomy, with unknown ovarian status or six weeks
or more following bilateral oophorectomy with or without hysterectomy. Women who
have self-identified at least one moderate to severe of the following symptoms: vaginal
dryness, vaginal and/or vulvar irritation or itching, dysuria; vaginal pain associated with
sexual activity; vaginal bleeding associated with sexual activity. Women between 40 and
75 years of age. Women having a low maturation index (no greater part of guidance
than 5% of superficial cells on vaginal smear). Women having a vaginal pH above 5.
Normal mammography within 24 months of enrolment. Normal breast examination.
No former or present narcotic addiction or alcoholism. Bodyweight within 18.5 and 29.
9 of ideal bodyweight according to body mass index (BMI) (WHO). No hepatic or renal
impairment or condition known to affect drug or steroid metabolism. Normal baseline
hematology, clinical chemistry, and urinalysis. Endometrial thickness of 4mmor less at
transvaginal ultrasonography
Exclusion: undiagnosed abnormal genital bleeding, previous diagnosis of cancer, except
skin cancer (non-melanoma), history of hormone-dependant cancer (uterus, breast),
active or history of thromboembolic disease, significant metabolic or endocrine disease,
clinically significant gastrointestinal, liver or gallbladder disease, migraine headache,
diabetes mellitus not controlled by conventional therapy, eczema, cutaneous allergies.
significant complication on previous hormonal therapy., use of hormonal implants < 6
months prior to study entry. Any oral estrogen, progestin or DHEA exposure (HRT and
vaginal creams) or use of natural estrogens (phytoestrogens) or herbal products to treat
postmenopausal symptoms in the 8 weeks prior to baseline assessments
Interventions 1. Intravaginal ovule of 1.8% (23.4 mg) DHEA
2. Intravaginal ovule of 1.0% (13 mg) DHEA
3. Intravaginal ovule of 1.8% (6.5 mg) DHEA
4. Intravaginal ovule of 0% (0 mg) DHEA (placebo)
Treatment duration: daily for 1 week
Outcomes Serum DHEA and its metabolites, safety profile
Notes “This was a 7-day study only aimed at pharmacokinetics. Safety is always studied but no
significant side effect has been observed”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States “randomized”, randomisation tech-
nique not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk States “double-blinded”, unclear how
blinding was done
56Dehydroepiandrosterone for women in the peri- or postmenopausal phase (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Labrie 2008 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if there were any dropouts
Blinding of outcome assessment Unclear risk Unclear as blinding is not clear and the
outcomes may have been influenced if the
study was not blinded
Selective reporting (reporting bias) Unclear risk Official protocol not available or found
Other bias Unclear risk Unclear
Labrie 2009a
Methods Design: multicentre, randomised, placebo-controlled, parallel trial
Country: Canada
Participants Study population: n = 218 postmenopausal women (216 were included for ITT analysis)
(n = 53 (0.0% DHEA), n = 53 (0.25% DHEA), n = 56 (0.5% DHEA) and n = 54 (1.
0% DHEA)
The following informationwill only include the 0.0%(placebo) and 1.0%DHEAgroups
Age: median 58, range 49 to 70 years (placebo) and median 59, range 46 to 69 years(1.
0% DHEA)
BMI: between 18.5 and 35 kg/m²
Inclusion: nomenses for at least 1 year; or FSH levels of 40mIU/mLormore (within 60 d
before day 1) in women with nomenses for 6months or more but less than 12months, or
hysterectomizedwomenwhowere premenopausal at the time of hysterectomy; or 6weeks
or more (of screening visit) after bilateral oophorectomy. Women having self-identified
at least one moderate to severe of the following symptoms: vaginal dryness (none, mild,
moderate, or severe); vaginal, vulvar irritation or itching (none,mild,moderate, or severe)
; vaginal pain associated with sexual activity (none, mild, moderate, or severe)
Exclusion: undiagnosed abnormal genital bleeding. Previous diagnosis of cancer, except
skin cancer (nonmelanoma). Endometrial hyperplasia at biopsy performed at screening
or endometrial cancer. Active or history of thromboembolic disease. Significantmetabolic
or endocrine disease. Clinically significant gastrointestinal, liver, or gallbladder disease.
Recurrent migraine headache not controlled by conventional therapy. Diabetes mellitus
not controlled by conventional therapy. Significant complication on previous hormone
therapy. Use of estrogen-alone injectable drug therapy or progestin implant within 3
months before study entry (screening visit)
Interventions 1. intravaginal ovule containing 0,25% DHEA = 3.25 mg DHEA
2. intravaginal ovule containing 0,5% DHEA = 6.5 mg DHEA
3. intravaginal ovule containing 1.0% DHEA = 13 mg DHEA
4. intravaginal ovule containing 0,0% DHEA = 0 mg DHEA
Treatment duration: all daily for 12 weeks
The DHEA ovules or suppositories (Vaginorm) containing Prasterone in a lipophilic
base were manufactured by Recipharm (Karlskoga, Sweden)
Outcomes Signs and symptoms of vaginal atrophy (e.g. quality of life, libido, sexual dysfunction)
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Notes We have only included the results of 0.0% (placebo) and 1.0% (highest DHEA dose)
treatment for meta-analysis
Study reported a significant decrease in severity scores of vaginal dryness and pain at
sexual activity. For pain at sexual activity there was a decrease of 58% for the 1.0%DHEA
cream, with P < 0.0001 versus placebo. And for vaginal dryness there was a decrease of
68% for the 1.0% DHEA cream, with P = 0.014 versus placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized” but unclear which ran-
domisation technique has been used
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk States double blind, but blinding process is
not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk “The percentage of participants who had
questionnaire data through the final visit at
week 12was greater than 90% in each treat-
ment group for each questionnaire; there-
fore, it was not considered necessary to con-
duct a completers or evaluable population
analysis in addition to the ITT analysis.”
“Missing values for any endpoint for a par-
ticipant were replaced using a last value”
Blinding of outcome assessment Unclear risk Unclear as blinding is not clear and the
outcomes may have been influenced if the
study was not blinded
Selective reporting (reporting bias) Unclear risk Original protocol not found or available
Other bias Unclear risk Unclear
Lasco 2001
Methods Design: single centre, randomised, placebo-controlled, parallel trial
Country: Italy
Participants Study population: n = 20 postmenopausal women (n = 10 (DHEA) and n = 10 (placebo)
Age: 57.6 ± 4.5 (DHEA) and 55.1 ± 3.8 (placebo) years
BMI: 23.7 ± 3.2 (DHEA) and 23.9 ± 3.1 (placebo) kg/m²
Inclusion: 20 healthy adrenal-androgen deficient postmenopausal women (serum
DHEA-S concentrations < 2.5 µmol/L), who had never been treated
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with hormonal replacement therapy
Exclusion: acute or chronic illnesses were excluded by means of clinical examination
and routine laboratory investigation. Exclusion criteria also included history of diabetes
mellitus and other metabolic or endocrine disorders
Interventions 1. Oral micronized DHEA 25 mg
2. Identical placebo tablet
Treatment duration: once daily for 12 months
Outcomes Metabolic effects, adverse effects
Notes Age and BMI are expressed as mean ± SD
“No relevant side effects were recorded during the study period; only one patient devel-
oped slight acne at the beginning of treatment and it disappeared spontaneously later.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Information retrieved after contacting the
author. “We assigned subjects to treatment
by using a computerized randomization/
enrollment system which assigned unique
randomization numbers.”
Allocation concealment (selection bias) Low risk After contacting author. “Treatment as-
signment was revealed at the end of the
study and the list was kept by Professor Cu-
cinotta D. Treatment assignment was re-
vealed at the end of the study or follow-
ing the onset of an adverse event (only one
case).”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “DHEA was provided as tablets of a mi-
cronized galenic compound, prepared by a
local chemist’s shop. In group 2 patients re-
ceived an identical placebo tablet.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data were addressed
Blinding of outcome assessment Low risk Blinding unlikely to have been broken
Selective reporting (reporting bias) Unclear risk Official protocol not found or available
Other bias Unclear risk Unclear
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Methods Design: single centre, randomised, placebo-controlled, crossover trial
Country: USA
Recruitment: recruited by newspaper advertisement who were paid USD 300.00 for
their participation
Participants Study population: N = 48 postmenopausal women
Age: 63.5 ± 6.85 years
BMI: 27.46 ± 4.36, range 19-35 kg/m²
Inclusion: participants met theWorld Health Organization’s criteria for postmenopausal
status of one year’s absence of menses or bilateral ovariectomy that preceded the study by
at least one year. No participant was using any form of hormone replacement therapy.
All women enrolled had a normal mammogram within the prior year and a normal Pap
smear within the prior three years
Exclusion: participants were excluded if a pre-enrolment medical evaluation revealed
contraindications to DHEA, estrogen or androgen treatment (i.e. personal history ofor
active breast cancer or other estrogen-dependent neoplasms, acute liver disease, undi-
agnosed vaginal bleeding, uncontrolled hyper- tension, deep venous thrombosis, pul-
monary embolus, history of clotting disorders, history of psychiatric or cognitive dis-
orders). Women whose pre-enrolment assays of DHEAS, estradiol or testosterone were
above the normal post- menopausal women’s range or whose body mass index (BMI)
exceeded 35 were excluded. Our finals ample included women with BMIs from Use
of substances that influence cognition( e.g. amphetamines, benzodiazepines, narcotics,
nicotine, steroid hormones, and steroid receptor antagonists) was also grounds for ex-
clusion, as was a serious physical illness within the last year
Interventions 1. Oral DHEA capsules 50 mg
2. Placebo identical to DHEA capsule, containing lactose
Treatment duration: daily for 4 weeks
Outcomes Sex steroid serum levels, affective measures (using BeckDepression Inventory and Symp-
toms Checklist-90) and cognitive measures
Notes Age and BMI are expressed as mean ± SD
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants were assigned to receive
DHEA or placebo in a block-randomiza-
tion scheme”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Low risk Placebo (identical in appearance to DHEA
capsules). “All investigators and partici-
pants were blind to treatment status”
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if there were any withdrawals
Blinding of outcome assessment Low risk Blinding unlikely to have been broken and
self-administered questionnaires
Selective reporting (reporting bias) Unclear risk Official protocol not found or available
Other bias Unclear risk Unclear
Mortola 1990
Methods Design: single centre, randomised, placebo-controlled, crossover trial
Country: USA
Participants Study population: n = 6 postmenopausal women (one woman had undergone bilateral
oophorectomy and the remainder had spontaneous menopause of more than 1 year
duration)
Age: 46 to 61 years
Inclusion: menopause was confirmed by elevated FSH and LH levels. No subject had
taken hormone replacement therapy or other prescribedmedication for the previous year
Exclusion: medical illness was excluded by history, physical examination, serum chem-
istry profile, including renal liver and thyroid panels, urinalysis, and complete blood
count
Interventions 1. Oral DHEA 1600 mg (4 x 400 mg)
2. Placebo
Both were packaged in gelatin capsules
Treatment duration: daily for 28 days, followed by washout period of two weeks and
then followed by a 28 days crossover treatment
Outcomes Endocrine-metabolic parameters, adverse effects
Notes Unable to contact the authors
One subject reported increased facial hair during DHEA treatment, and one did so
during placebo administration. No changes in sexual drive or appetite were reported. No
other adverse consequences were noted. Unclear how many women were randomised to
each treatment group. Therefore not possible to include in meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”, randomisation tech-
nique was not described
Allocation concealment (selection bias) Unclear risk Not stated
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Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if there were any dropouts
Blinding of outcome assessment Unclear risk May have influenced the outcomes if not
blinded
Selective reporting (reporting bias) Unclear risk Official protocol not found or available
Other bias Unclear risk Unclear
Nouveau 2008
Methods Design: single centre, randomised, controlled, parallel trial
Country: France
Participants Study population: n = 40 postmenopausal women (n = 20 (DHEA), n = 20 (placebo))
Age: 55 to 70 years (mean 60 ± 4)
Interventions 1. DHEA cream (containing 1% DHEA)
2. Placebo, identical in appearance to active treatment
Treatment duration: twice daily applied to the face and the back of one hand for 4
months
Outcomes Skin changes, adverse effects
Notes Each volunteer was left free to apply the preferred amount of cream according to their
usual habits
”Any sign of androgen excess such as body hair growth or greasy skin was not sponta-
neously reported. Ten weeks after the beginning of the treatment, one woman of the
DHEA group presented some lesions of acne which resolved without any complemen-
tary treatment, just by reducing the frequency of cream application during the following
2 weeks. The code was not broken for this volunteer.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”The volunteers had been allocated using
a randomization procedure for both the
treatment group and the application side.
The randomization list was balanced by a
group of 10 using the procedure Proc Plan
from the SAS statistical software release 8.
1.“
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Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Low risk States to be double blinded” “The volun-
teers were divided into two groups; one re-
ceived a cream preparation containing 1%
DHEA and the other received the vehicle
only, i.e. exactly the same formulationwith-
out the active ingredient (DHEA).”
“onewomanof theDHEAgrouppresented
some lesions of acne which resolved with-
out any complementary treatment, just by
reducing the frequency of cream applica-
tion during the following 2 weeks. The
code was not broken for this volunteer”.
Very likely to have been double-blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if there were any dropouts
Blinding of outcome assessment Low risk Self-assessment, blinding unlike to have
been broken
Selective reporting (reporting bias) Unclear risk Official protocol not available or found
Other bias Unclear risk “A little more than half of the subjects were
under hormone replacement therapy, i.e.
estrogen-progestin treatment (10 in the ve-
hicle group, 12 in theDHEA treated group,
the mean number of years on therapy was
5±4 years).”
Panjari 2009
Methods Design: single centre, randomised, placebo-controlled, parallel trial
Country: Australia
Enrolment: women from metropolitan Melbourne, Australia participated between
February 2006 and April 2008
Participants Study population: n = 93 postmenopausal women (n = 47 (DHEA) and n = 46 (placebo)
Age: 55.1 ± 4,5 (DHEA), 53.9 ± 4.7 (placebo), total range between 40 and 65 years
BMI: 24.5 ± 3.5 (DHEA) and 26.8 ± 3.4 (placebo)
Comorbidity: hypoactive sexual desire disorder, low libido
Inclusion: all participants were 12 months postmenopause and were required to have a
normal mammogram and Pap smear and endometrial double thickness 4 mm and no
other abnormal findings on transvaginal ultrasound. Womenwere required to be sexually
active, defined as being involved in any form of sexual activity at least once a month. All
participants demonstrated evidence of hypoactive sexual desire disorder (HSDD) by an-
swering affirmatively five questions about changes in their sex life following menopause,
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including a meaningful decrease in level of desire and sexual activity that was concerning
to them consistent with the DSM IV definition
Exclusion: a bodymass index (BMI) <18kg/m2 or >34kg/m2, dyspareunia, undiagnosed
genital bleeding, severe depression, or had pharmacological treatment for depression
within 2 months of the screening visit or a history of severe psychiatric illness. Women
with more than three satisfactory sexual events per week were excluded. Use of androgen
therapy (testosterone implant within the last 28 weeks, transdermal testosterone cream
within the last 8 weeks, tibolone within the last 12 weeks, oral testosterone within the last
4 weeks, and injected testosterone within the last 6 weeks) or estrogen, including vaginal
conjugated equine estrogen, vaginal estrogen ring, or estrogen-progestin combinations
in the last 2months were excluded (use of vaginal estriol or low dose estradiol pessaries or
creamwas allowed). Use of phytoestrogens within 1week prior to screening and therapies
known to induce liver enzyme metabolism or alter the metabolism of DHEA resulted
in exclusion.Women were also excluded if they had any serious medical conditions,
history of breast or gynecological cancer, abnormal TSH level or abnormal liver function,
moderate to severe acne, hirsutism, androgenic alopecia, or use of antiandrogen therapy
for acne or hirsutism in the preceding 5 years, reported alcohol consumption more than
three standard drinks per day, or had, in the opinion of the investigators, any clinically
significant pretreatment illness, which would impact on the health and well-being of the
woman or her ability to participate in the study
Interventions 1. Oral DHEA capsule 50 mg
2. Identical placebo
Treatment duration: once daily for 1 year
Outcomes Efficacy measurements (sexual function, quality of life), safety assessments (adverse ef-
fects), hormone measurements (serum levels of e.g. DHEA)
Notes Age and BMI are expressed as mean ± SD
Androgenic adverse events occurred exclusively in the DHEA group with three reported
instances of acne and two of increased facial hair. One participant had both acne and in-
creased facial hair and she withdrew from the study after 26 weeks. The other participant
with facial hair also withdrew after 26 weeks. The three cases of acne were all classified
as mild. There were no reported instances of voice deepening, alopecia, or clitoromegaly
There were a total of 55 adverse effects reported of which 24 adverse events reported in
the placebo group and 31 in the DHEA group. Only androgenic adverse events were
specified (5/55)
Quality of life was measured by PGWB score (psychological general wellbeing) (range 0
to 110)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was computer generated
by Endorecherche, Canada with stratifica-
tion for hysterectomy status.”
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Panjari 2009 (Continued)
Allocation concealment (selection bias) Low risk “Allocation concealment wasmaintained as
treatment codes were controlled by the Al-
fredHospital PharmacyMelbourne, which
dispensed the coded medication directly to
participants in 3-month batches.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The investigators, study center person-
nel, and participants remained blinded
throughout the study.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Seventy-nine of the 89 women (89%)
completed the 26-week treatment period.
Eighty-five women were included in the
26-week efficacy analysis and 63 women
who completed 52 weeks were included in
the safety analyses”
All outcomes have been addressed and rea-
sons for withdrawal have been stated
Blinding of outcome assessment Low risk Blinding unlikely to have been broken
Selective reporting (reporting bias) Unclear risk Official protocol not available or found
Other bias Unclear risk Unclear
Pluchino 2008
Methods Design: single, randomised, controlled (head-to-head), parallel trial
Country: Italy
Enrolment: patients were divided in two groups according only to their DHEA and
DHEAS plasma levels, i.e. higher than or lower than 2.40 ng/mL for DHEA and 0.55
g/mL for DHEAS
Participants Study population: n = 32 postmenopausal women (n = 10 (DHEA), n = 10 (HRT) and
n = 12 (HRT + DHEA) The HRT + DHEA group was not randomised, therefore we
will not include this group in our further analyses
Age: between 50 and 58 years
BMI: 27.65 ± 1.84 (DHEA), 28.65 ± 2.04 (HRT)
Inclusion: all subjects had natural menopause and were healthy
Exclusion: previous or current endocrine disorders, such as thyroid or adrenal dysfunc-
tion and altered prolactin circulating levels; treatments for cardiovascular diseases, hy-
pertension or psychiatric disorders; previous or current hormonal treatments known to
influence endocrine function (including HRT); smoking; presence of any kind of pelvic
and breast disease. Natural menopause was defined retrospectively after 12 consecutive
months without natural menstrual periods and age at menopause was the age at last
menstruation
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Pluchino 2008 (Continued)
Interventions 1. Oral 10 mg DHEA supplementation daily
2. HRT consisting out of a twice weekly transdermal 50 µg estradiol (TE) patch (Der-
mestril 50, Rottapharm) + oral micronized progesterone (mP) 100 mg/day (prometrium
100, Rottapharm)
3. Both 1 and 2. (this group was not randomised and therefore not included)
Treatment duration: 12 months
Outcomes Hormonal milieu and adverse effects
Notes Reported that there were no adverse effects
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was made using a com-
puter-generated block random-permuta-
tion procedure.”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
High risk Not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk “All the patients enrolled in the study com-
pleted the follow-up, without any adverse
events.”
Blinding of outcome assessment High risk Outcomes may have been influences (not
blinded)
Selective reporting (reporting bias) Unclear risk Official protocol not found or available
Other bias Unclear risk Unclear
Silvestri 2005
Methods Design: randomised, double-blind, controlled (head-to-head), double crossover trial
Country: Italy
Participants Study population: n = 30 postmenopausal women were recruited, 16 were randomised
after screening
Age: 45 to 70 years
Inclusion: menopausal status was assessed by the absence of menses of at least 6 months
and by plasma levels of estradiol 17 < 25 ng/ml, coupled with baseline FSH > 40 mIU/
mL. Age between 45 and 70 years, presence of more than two risk factors for coronary
artery disease causing a 10 year cardiovascular risk of 40% (Table 1), intact uterus.
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Silvestri 2005 (Continued)
No subject had taken any cholesterol-lowering agent, estrogen therapy, or antioxidant
vitamin supplements during the previous 2 months. Aspirin and non-steroidal anti-
inflammatory agents were stopped 10 days prior to the study
Exclusion: patients with clinically significant findings on physical exam or presence of
known clinically significant diseases interfering with study evaluation, those currently
using medications (or products) that interfere with forearm blood flow were excluded
from the study
Interventions 1. Oral DHEA-s 50 mg
2. Oral conjugated equine estrogen (CEE) 0.625 mg
3. Oral tibolone 2.5 mg
Treatment duration: 4 weeks, washout of 1 week, followed by crossover treatment
Outcomes Endothelial function
Notes Information retrieved after contacting author. “No adverse events in any of the treatment
phases” - “we did not measure patients related outcomes”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk After contacting author: “Randomisation
was obtained through a computer-gener-
ated random list”
Allocation concealment (selection bias) Low risk After contacting author: “Drugs were ad-
ministered by investigators unaware of the
clinical data and not involved in the study
assessments. All patients were naive on the
treatments.”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk States to be “double-blinded”, however it
is a head-to-head trial, everyone received
an active treatment. Unlikely that all ac-
tive tablets had identical appearances un-
less they have usedmultiple placebo tablets.
However this is unknown
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if there were any dropouts
Blinding of outcome assessment Unclear risk If blinding was broken it may have influ-
enced the outcomes
Selective reporting (reporting bias) Unclear risk Official protocol not found or available
Other bias Unclear risk Unclear
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Stanczyk 2009
Methods Design: single centre, randomised, placebo-controlled, parallel trial
Country: USA
Participants Study population: n = 20 postmenopausal women (after recruiting and screening of 58
women) (n = 10 (DHEA) and n = 10 (placebo))
Age: 55 to 65 years
BMI: ranged from 28 to 33 kg/m²
Inclusion: healthy postmenopausal women, not taking hormone therapy for at least
3 months or ingesting prescription or non-prescription herbal medications. Post-
menopausal status was determined by menstrual cycle history, as well as follicle-stimu-
lating hormone (> 25 mIU/mL) and E2 (G25 pg/mL) levels at time of entry into the
study
Exclusion: hormone use or seriousmedical conditions requiring prescriptionmedications
or non-compliance with the number of study-related visits
Interventions 1. Oral tablet containing 25 mg of DHEA
2. Placebo tablet (identical)
Treatment duration: daily for 6 months
Outcomes Pharmokinetics and metabolites, adverse effects
Notes Reported that “there were no adverse effects reported by any of the women”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization schedule was gener-
ated using the Statistical Analysis Systems
software.”
Allocation concealment (selection bias) Low risk “Identical-looking bottles were serially
numbered from 1 to 20. They were filled
with drug or placebo according to the ran-
domization schedule by the study phar-
macy that kept the randomization sched-
ule in a locked, secure cabinet. The women
were assigned sequentially from 1 to 20.”
“The study drug allocation was unblinded
only upon completion of the entire study”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The individuals examining and question-
ing the women did not know the therapy
to which the woman was assigned, as the
drug and placebo tablets looked identical,
including the bottles containing the tablets,
which were identified only with the study
number.”
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reasons for withdrawal have been stated
and only data from women who finished
the trial have been used for meta-analysis
Blinding of outcome assessment Low risk Blinding unlikely to have been broken
Selective reporting (reporting bias) Unclear risk Official protocol not available or found
Other bias Unclear risk “This work was supported in part by grant
M01 RR-43 from the General Clinical Re-
search Center branch of the National Cen-
ter for Research Resources, National Insti-
tutes of Health”
Stangl 2010
Methods Design: single centre, randomised, placebo-controlled, crossover trial
Country: USA
Recruitment: all participants were volunteers recruited by newspaper advertisement and
were paid USD 300.00 for their participation
Participants Study population: n = 24 postmenopausal women
Age: 65.25 ± 7.89, range 55 to 80 years
BMI: 27.70 ± 3.85 kg/m²
Inclusion: participantsmet theWorldHealthOrganization’s criteria for post-menopausal
status of one year’s absence of menses or bilateral ovariectomy that preceded the study
by at least one year
Exclusion: participants were excluded if a pre-enrolment medical evaluation revealed
contraindications to DHEA, estrogen or androgen treatment (e.g. personal history of, or
active, breast cancer or other estrogen-dependent neoplasms,history of clotting disorders,
). Women whose pre-enrolment assays of DHEAS, estradiol or testosterone were above
the normal postmenopausal women’s range or BMI > 35were excluded.Use of substances
that influence cognition (e.g. amphetamines, benzodiazepines, nicotine)was also grounds
for exclusion, as was a serious physical illness within the last year. All women enrolled
had a normal mammogram within the prior year and a normal Pap smear within the
prior three years
Interventions 1. 50 mg of oral DHEA
2. Identical placebo (consisted of lactose)
Treatment duration: 4 weeks, 1 week washout, followed by 4 weeks crossover treatment
Outcomes Cognitive and affective measures (including BDI and SCL 90-R)
Notes Age and BMI are expressed as mean ± SD
BDI = Beck Depression Inventory
SCL 90-R = Symptom Checklist 90-R
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Stangl 2010 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants were assigned to receive
DHEA or placebo in a block-randomiza-
tion scheme.”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Low risk “All investigators and participants were
blind to treatment status.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if there were any dropouts
Blinding of outcome assessment Low risk Blinding unlikely to have been broken and
self-assessment outcomes
Selective reporting (reporting bias) Unclear risk Protocol not found or available. Adverse ef-
fects were investigated, but not reported
Other bias Unclear risk Unclear
Stomati 1999
Methods Design: single centre, randomised, controlled (head-to-head), parallel study
Country: Italy
Participants Study population: n = 22 postmenopausal women (n = 8 (DHEAS), n = 8 (estradiol), n
= 6 (DHEAS + estradiol)
Age: range 50 to 55 years
BMI: normal body mass index - not specified
Exclusion: previous or current estrogen-dependent neoplasia, thromboembolic disease,
liver, pancreatic or renal disease and diabetes mellitus
Interventions 1. 50 mg of oral DHEAS daily
2. 50 mg of oral DHEAS daily + 50 µg estradiol patch
3. 50 µg estradiol patch continuously
Treatment duration: three months
Outcomes Neuroendocrine tests, subjective symptoms (e.g. by using Kupperman questionaire),
hormonal assays
Notes “No side effects requiring interruption of treatment were reported in any group during
the three months of therapy.”
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Stomati 1999 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly divided in three
groups, according to the type of treatment”
- randomisation technique unknown
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
High risk Not blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No dropouts due to side effects, unclear if
there were any other withdrawals
Blinding of outcome assessment High risk Not blinded, outcomes may have been af-
fected as everyone received an active treat-
ment
Selective reporting (reporting bias) Unclear risk Protocol not found or available
Other bias Unclear risk Unclear
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Barton 2006 Not all menopausal women
Bates 1995 Study was aimed at pharmacokinetics. No other data available (unsuccessful in contacting authors for
additional data)
Burger 2003 No full text available. No additional data available (authors were contacted)
Buster 1992 No full text available. Study was aimed at pharmacokinetics. Unsuccessful in contacting authors for addi-
tional data
Buster 2009 Non-RCT
Calvo 2008 Study was aimed at pharmacokinetics. No other data available
Carranza-Lira 2002 Quasi-randomised (alternate allocation)
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(Continued)
Casson 1993 Study was aimed at pharmacokinetics. No other data available (unsuccessful in contacting authors for
additional data)
Casson 1995 Study was aimed at pharmacokinetics. No other data available (unsuccessful in contacting authors for
additional data)
Caufriez 2013 Study was aimed at pharmacokinetics and sleep. Unsuccessful in contacting authors for additional data
Chassany 2000 Non-RCT
Hackbert 2002 Treatment duration < 1 week
Hartkamp 2004 Not all menopausal women
Kamath 1998 Premenopausal women
Labrie 2013 Non-RCT
Lovas 2003 Not all menopausal women
Ott 2014 Non-RCT
Pisarska 1998 No full text available. Study was aimed at pharmacokinetics. Unsuccessful in contacting authors for addi-
tional data
Rodrigo Pegado 2012 Non-RCT
Sanchez-Guerrero 2008 Not all menopausal women
Stein 2011 Premenopausal women
Stoll 1999 Non-RCT
Virkki 2010 Not all menopausal women
Yasui 2012 Non-RCT
Zouboulis 2012 Non-RCT
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Characteristics of studies awaiting assessment [ordered by study ID]
Igwebuike 2008
Methods Design: single centre, randomised, placebo-controlled trial
Participants Study population: n = 31 postmenopausal women (n = 17 (DHEA), n = 14 (placebo))
Age: 64.6 ± 1.0 years
Race: Caucasian
Inclusion: postmenopausal women
Exclusion: participants with a plasma concentration of DHEA-S greater than 110 g/mL or with evidence of diseases
such as diabetes, cardiovascular disease, or thyroid dysfunction were excluded due to the potential effects these diseases
may have on the outcomemeasures. Participants using psychotropic drugs, progesterone, testosterone, corticosteroids,
or DHEA within the preceding 6 months were excluded
Interventions 1. Oral DHEA 50 mg plus exercise training
2. Placebo plus exercise training
Treatment duration: daily for 12 weeks
Outcomes The effects of combined endurance and resistance training on improvements in body composition, physical perfor-
mance, and cardiometabolic risk
Notes Age is expressed as mean ± SD. Did not report any of the outcomes we are investigating
Labrie 2007
Methods Design: randomised, placebo-controlled, parallel trial
Participants Study population: n = 75 postmenopausal women
Age: 60 to 65 years
Race: Caucasian
BMI: 18.5 to 29.9 kg/m²
Inclusion: healthy postmenopausal Caucasian women aged 60 to 65 years
Exclusion: no subject had taken hormone replacement therapy during the previous 6 months. No endocrine disorder,
and none was under treatment with lipid- or glucose-lowering agents. No active or history of thromboembolic
disease, significant metabolic or endocrine disease and no clinically significant gastrointestinal, liver or gallbladder
disease. No migraine and no diabetes mellitus not controlled by conventional therapy. No corticosteroid treatment
< 6 weeks of study entry as well as treatment with -carotenoid, retinoic acid, hydroquinone, -hydroxyacid (including
inhaled, topical or oral). No hypertension equal to or above 160/95 mmHg or not controlled by standard therapy as
well as no confirmed clinically significant depression or confirmed severe psychiatric disturbance. No administration
of any investigational drug < 30 days of screening visit or previous treatment with androgens or anabolic steroids
within 6 months prior to the screening visit. There was no exposure to or use of antidepressants, antipsychotics, or
analgesics, < 30 days prior to enrollment. Smoking any number of cigarettes. No former or present narcotic addiction
or alcoholism. BMI between 18.5 and 29.9 kg/m². There was no hepatic or renal impairment or condition known
to affect drug or steroid metabolism
Interventions 1. 2.0% DHEA cream (emulsion)
2. 1.0% DHEA cream (emulsion)
3. 0,3% DHEA cream (emulsion)
4. 0,1% DHEA cream (emulsion)
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5. Placebo (emulsion)
Treatment duration: applied twice daily on the face, upper chest, arms and legs for 7 days
Outcomes Metabolism of DHEA and related steroid
Notes Study is aimed at pharmakinetics. Did not report any of our outcomes. Author was contacted, waiting for response
Labrie 2007a
Methods Design: randomised controlled parallel trial
Country: Canada
Participants Study population: 36 healthy postmenopausal women (n = 12 DHEA cream, n = 12 DHEA gel, n = 12 oral DHEA)
Age: between 60 and 70 years
Exclusion: metabolic or endocrine disorder, coronarian disease or hypertension. No treatment with androgens or
anabolic steroids
Interventions 1. 100 mg oral DHEA (two capsules of 50 mg)
2. 4 g of 10% DHEA gel applied on a total 30 cm × 30 cm area of the thighs
3. 4 g of 10% DHEA cream applied on a total 30 cm × 30 cm area of the thighs
Treatment duration: daily for 14 days
Outcomes Bioavailability and metabolism of DHEA
Notes No outcomes for inclusion in our review reported, author was contacted to request additional data, awaiting
Labrie 2008a
Methods Design: randomised, controlled, parallel trial
Country: Canada
Participants Study population: 150 healthy postmenopausal women
Age: between 60 and 65 years
Race: Caucasian
Exclusion: hormone replacement therapy during the previous 6 months. Endorcrine disorder, treatment with lipid or
glucose-lowering agents, thromboembolic disease, metabolic or endocrine disease, gastrointestinal, liver or gallbladder
disease. Migraine or diabetis mellitus controlled by conventional therapy. corticosteroid treatment <6 weeks of study
entry or treatment with -carotenoid, retinoic acid, hydroquinone, -hydroxyacid (including inhaled, topical or oral)
. administration of any investigational drug within 30 days of screening visit or previous treatment with androgens
or anabolic steroids < 6 months prior to the screening visit. There was no exposure to or use of antidepressants,
antipsychotics, or analgesics, < 30 days prior to enrolment. Smoking
Interventions 1. 3 g 0.3% DHEA emulsion
2. Placebo emulsion
Treatment duration: twice daily for 12 months
Outcomes Serum DHEA and its metabolites
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Notes No outcomes for inclusion in our review reported, author was contacted to request additional data, awaiting response
Characteristics of ongoing studies [ordered by study ID]
Labrie 2005
Trial name or title Phase II-III Placebo-Controlled, Study to Evaluate the Effects of DHEA on Vasomotor Symptoms (Hot
Flashes) in Postmenopausal Women
Methods Randomised, parallel trial
Participants Inclusion: healthy postmenopausal women with 50 or more moderate to severe hot flushes, between 40 to
70 years of age
Exclusion:
• Body mass index (BMI) of 35 kg/m2 or more
• Significant metabolic and endocrine diseases
• Diagnosis of cancer
• Use of steroids or drugs that interfere with the metabolism of estrogen
• Use of any systemic estrogen, progestin, or DHEA in the eight weeks prior to randomisation
• Use of alternative therapies or natural products to treat postmenopausal symptoms in the four weeks
prior to randomisation
• Palpable fibroids or uterine prolapse: Grade 2 or 3
• Cigarette smoking
Interventions 1. DHEA (prasterone)
2. Placebo
Treatment duration: 16 weeks
Outcomes The number and intensity of hot flashes and evaluation of safety, quality of life, psychological general wellbeing
and sexual life by questionnaires
Starting date August 2005
Contact information Clinique des Traitements Hormonaux Sainte-Foy, Quebec, Canada, G1V 4G2
Notes ClinicalTrials.gov identifier: NCT00317148
Labrie 2014
Trial name or title Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause
Methods Randomised, parallel trial
Participants Inclusion:
• Postmenopausal women (hysterectomized or not)
• Women between 40 and 80 years of age
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Labrie 2014 (Continued)
• Women having ≤ 5% of superficial cells on vaginal smear at baseline
• Women having a vaginal pH above 5 at baseline
• Women who have self-identified moderate or severe symptom(s) of vaginal atrophy
• Willing to participate in the study and sign an informed consent
Exclusion:
• Previous enrolment in EndoCeutics studies performed with intravaginal DHEA
• Previous diagnosis of cancer, except skin cancer (non melanoma)
• Clinically significant metabolic or endocrine disease (including diabetes mellitus) not controlled by
medication
• The administration of any investigational drug within 30 days of screening visit
• Clinically significant abnormal serum biochemistry, urinalysis or haematology
Interventions 1. Intravaginal DHEA
2. Placebo
Treatment duration: 12 weeks
Outcomes Vaginal maturation index, vaginal pH, vulvovaginal atrophy symptom, tolerance to intravaginal prasterone
(by evaluation of vaginal mucosa)
Starting date February 2014
Contact information Contact: Isabelle Côté, B. Sc. CCRP. 1-855-653-0033 ext 204. isabelle.cote@endoceutics.com
Notes ClinicalTrials.gov identifier: NCT02013544
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D A T A A N D A N A L Y S E S
Comparison 1. DHEA versus control (placebo or no treatment)




participants Statistical method Effect size
1 QoL/wellbeing (end scores) 9 Std. Mean Difference (Fixed, 95% CI) -0.04 [-0.20, 0.13]
2 Sensitivity analysis
QoL/wellbeing (end scores)
8 Std. Mean Difference (Fixed, 95% CI) 0.16 [-0.03, 0.34]
3 QoL (subgrouped on Low
Libido/HSDD)
9 Std. Mean Difference (Fixed, 95% CI) Subtotals only
3.1 Low Libido/HSDD 2 Std. Mean Difference (Fixed, 95% CI) 0.10 [-0.26, 0.46]
3.2 Libido normal/unknown 7 Std. Mean Difference (Fixed, 95% CI) -0.08 [-0.27, 0.11]
4 QoL (subgrouped on treatment
duration)
9 Std. Mean Difference (Fixed, 95% CI) -0.04 [-0.20, 0.13]
4.1 <6 weeks 3 Std. Mean Difference (Fixed, 95% CI) 0.23 [-0.11, 0.57]
4.2 6 to 26 weeks 3 Std. Mean Difference (Fixed, 95% CI) 0.13 [-0.13, 0.39]
4.3 >26 weeks 3 Std. Mean Difference (Fixed, 95% CI) -0.46 [-0.75, -0.16]
5 QoL/General Wellbeing (change
scores)
2 Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 Side-effects 5 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Androgenic side-effects 1 92 Odds Ratio (M-H, Fixed, 95% CI) 6.57 [1.37, 31.59]
6.2 Acne 4 158 Odds Ratio (M-H, Fixed, 95% CI) 2.26 [0.56, 9.02]
6.3 Hirsutism 1 89 Odds Ratio (M-H, Fixed, 95% CI) 4.89 [0.23, 104.76]
7 Acne subgrouped on study
duration
4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 < 6 weeks 1 27 Odds Ratio (M-H, Fixed, 95% CI) 0.29 [0.01, 7.70]
7.2 >6 weeks to 26 weeks 1 22 Odds Ratio (M-H, Fixed, 95% CI) 2.74 [0.10, 74.87]
7.3 >26 weeks 2 109 Odds Ratio (M-H, Fixed, 95% CI) 5.25 [0.58, 47.36]
8 Menopausal symptoms
(continuous)
2 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 Endscores 1 17 Std. Mean Difference (IV, Fixed, 95% CI) 0.35 [-0.70, 1.40]
8.2 Change scores 1 66 Std. Mean Difference (IV, Fixed, 95% CI) 0.07 [-0.42, 0.55]
9 Menopausal symptoms
(dichotomous)
2 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
9.1 Flushes 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Hot flushes and
palpitations
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.3 Insomnia 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.4 Night sweats 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.5 Depression 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.6 Loss of libido 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.7 Vaginal dryness 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.8 Pruritis vulvae 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.9 Urethral syndrome 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.10 Tiredness 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Sexual Function (end scores) 6 Std. Mean Difference (Fixed, 95% CI) 0.19 [-0.01, 0.40]
11 Sexual function (end scores)
(sensitivity analysis)
5 Std. Mean Difference (Fixed, 95% CI) 0.31 [0.07, 0.55]
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Comparison 2. Oral DHEA versus control subgrouped by route of administration




participants Statistical method Effect size
1 QoL/wellbeing (change scores) 2 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Oral administration 1 66 Std. Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.53, 0.43]
1.2 Intravaginal application 1 107 Std. Mean Difference (IV, Fixed, 95% CI) 1.23 [0.82, 1.65]
2 Side-effects: acne 4 158 Odds Ratio (M-H, Fixed, 95% CI) 2.26 [0.56, 9.02]
2.1 Skin application 1 22 Odds Ratio (M-H, Fixed, 95% CI) 2.74 [0.10, 74.87]
2.2 Oral administration 3 136 Odds Ratio (M-H, Fixed, 95% CI) 2.16 [0.47, 9.96]
4 Sexual Function (end scores) 6 Std. Mean Difference (Fixed, 95% CI) 0.19 [-0.01, 0.40]
4.1 Oral administration 5 Std. Mean Difference (Fixed, 95% CI) 0.11 [-0.13, 0.35]
4.2 Intravaginal application 1 Std. Mean Difference (Fixed, 95% CI) 0.42 [0.03, 0.81]
Comparison 3. DHEA versus HT




participants Statistical method Effect size
1 QoL/General Wellbeing 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 ET 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Combined 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Tibolone 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Menopausal symptoms
(continuous)
2 Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 ET 1 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Combined 1 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Tibolone 1 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Sexual Function 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 ET/ET+P 2 41 Mean Difference (IV, Fixed, 95% CI) 1.26 [-0.21, 2.73]
4.2 Tibolone 1 24 Mean Difference (IV, Fixed, 95% CI) 4.60 [0.92, 8.28]
Comparison 4. DHEA versus HT (side effects) (dichotomous)




participants Statistical method Effect size
1 Acne 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 ET 1 50 Odds Ratio (M-H, Fixed, 95% CI) 17.0 [0.90, 320.37]
1.2 Tibolone 1 50 Odds Ratio (M-H, Fixed, 95% CI) 17.0 [0.90, 320.37]
2 Hair loss 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 ET 1 50 Odds Ratio (M-H, Fixed, 95% CI) 10.67 [0.54, 209.64]
2.2 Tibolone 1 50 Odds Ratio (M-H, Fixed, 95% CI) 10.67 [0.54, 209.64]
3 Headache 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 ET 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.03 [0.00, 0.53]
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3.2 Tibolone 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.01, 4.04]
4 Nausea 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 ET 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.22 [0.04, 1.21]
4.2 Tibolone 1 50 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.13, 7.72]
5 Leg cramps 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 ET 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Tibolone 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Breast Tenderness 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 ET 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.07 [0.00, 1.40]
6.2 Tibolone 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 8.25]
7 Bloating 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 ET 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.09 [0.00, 1.84]
7.2 Tibolone 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.01, 4.04]
8 Weight gain 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 ET 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.09 [0.00, 1.84]
8.2 Tibolone 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.01, 4.04]
Comparison 5. DHEA versus HT (menopausal symptoms) (dichotomous)




participants Statistical method Effect size
1 Tiredness 1 100 Odds Ratio (M-H, Fixed, 95% CI) 1.26 [0.49, 3.26]
1.1 ET 1 50 Odds Ratio (M-H, Fixed, 95% CI) 1.26 [0.33, 4.84]
1.2 Tibolone 1 50 Odds Ratio (M-H, Fixed, 95% CI) 1.26 [0.33, 4.84]
2 Hot flushes and palpitations 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 ET 1 50 Odds Ratio (M-H, Fixed, 95% CI) 1.40 [0.28, 7.00]
2.2 Tibolone 1 50 Odds Ratio (M-H, Fixed, 95% CI) 1.40 [0.28, 7.00]
3 Night sweats 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 ET 1 50 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.18, 5.51]
3.2 Tibolone 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.14, 3.59]
4 Vaginal Dryness 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 ET 1 50 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 16.93]
4.2 Tibolone 1 50 Odds Ratio (M-H, Fixed, 95% CI) 3.12 [0.12, 80.39]
5 Pruritis Vulvae 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 ET 1 50 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 16.93]
5.2 Tibolone 1 50 Odds Ratio (M-H, Fixed, 95% CI) 3.12 [0.12, 80.39]
6 Urethral Syndrome 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 ET 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.48 [0.04, 5.65]
6.2 Tibolone 1 50 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 16.93]
7 Depression 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 ET 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 8.25]
7.2 Tibolone 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Loss of libido 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 ET 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 8.25]
8.2 Tibolone 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 DHEA versus control (placebo or no treatment), Outcome 1 QoL/wellbeing
(end scores).
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 1 DHEA versus control (placebo or no treatment)











IV,Fixed,95% CI IV,Fixed,95% CI
Bloch 2013 0.13 (0.3552) 5.8 % 0.13 [ -0.57, 0.83 ]
Dayal 2005 1.1518 (0.578) 2.2 % 1.15 [ 0.02, 2.28 ]
Finckh 2005 0.1417 (0.2088) 16.9 % 0.14 [ -0.27, 0.55 ]
Hirshman 2003 0.0195 (0.2582) 11.0 % 0.02 [ -0.49, 0.53 ]
Hirshman 2004 0.4799 (0.5896) 2.1 % 0.48 [ -0.68, 1.64 ]
Kritz-Silverstein 2008 -0.83 (0.1939) 19.6 % -0.83 [ -1.21, -0.45 ]
Merritt 2012 0.1314 (0.2044) 17.6 % 0.13 [ -0.27, 0.53 ]
Panjari 2009 0.09 (0.2143) 16.0 % 0.09 [ -0.33, 0.51 ]
Stangl 2010 0.2143 (0.2896) 8.8 % 0.21 [ -0.35, 0.78 ]
Total (95% CI) 100.0 % -0.04 [ -0.20, 0.13 ]
Heterogeneity: Chi2 = 24.51, df = 8 (P = 0.002); I2 =67%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 DHEA versus control (placebo or no treatment), Outcome 2 Sensitivity analysis
QoL/wellbeing (end scores).
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 1 DHEA versus control (placebo or no treatment)











IV,Fixed,95% CI IV,Fixed,95% CI
Bloch 2013 0.13 (0.3552) 7.2 % 0.13 [ -0.57, 0.83 ]
Dayal 2005 1.1518 (0.578) 2.7 % 1.15 [ 0.02, 2.28 ]
Finckh 2005 0.1417 (0.2088) 21.0 % 0.14 [ -0.27, 0.55 ]
Hirshman 2003 0.0195 (0.2582) 13.7 % 0.02 [ -0.49, 0.53 ]
Hirshman 2004 0.4799 (0.5896) 2.6 % 0.48 [ -0.68, 1.64 ]
Merritt 2012 0.1314 (0.2044) 21.9 % 0.13 [ -0.27, 0.53 ]
Panjari 2009 0.09 (0.2143) 19.9 % 0.09 [ -0.33, 0.51 ]
Stangl 2010 0.2143 (0.2896) 10.9 % 0.21 [ -0.35, 0.78 ]
Total (95% CI) 100.0 % 0.16 [ -0.03, 0.34 ]
Heterogeneity: Chi2 = 3.71, df = 7 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 DHEA versus control (placebo or no treatment), Outcome 3 QoL (subgrouped
on Low Libido/HSDD).
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 1 DHEA versus control (placebo or no treatment)











IV,Fixed,95% CI IV,Fixed,95% CI
1 Low Libido/HSDD
Bloch 2013 0.13 (0.3552) 26.7 % 0.13 [ -0.57, 0.83 ]
Panjari 2009 0.09 (0.2143) 73.3 % 0.09 [ -0.33, 0.51 ]
Subtotal (95% CI) 100.0 % 0.10 [ -0.26, 0.46 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
2 Libido normal/unknown
Dayal 2005 1.1518 (0.578) 2.8 % 1.15 [ 0.02, 2.28 ]
Finckh 2005 0.1417 (0.2088) 21.6 % 0.14 [ -0.27, 0.55 ]
Hirshman 2003 0.0195 (0.2582) 14.1 % 0.02 [ -0.49, 0.53 ]
Hirshman 2004 0.4799 (0.5896) 2.7 % 0.48 [ -0.68, 1.64 ]
Kritz-Silverstein 2008 -0.83 (0.1939) 25.0 % -0.83 [ -1.21, -0.45 ]
Merritt 2012 0.1314 (0.2044) 22.5 % 0.13 [ -0.27, 0.53 ]
Stangl 2010 0.2143 (0.2896) 11.2 % 0.21 [ -0.35, 0.78 ]
Subtotal (95% CI) 100.0 % -0.08 [ -0.27, 0.11 ]
Heterogeneity: Chi2 = 23.78, df = 6 (P = 0.00057); I2 =75%
Test for overall effect: Z = 0.78 (P = 0.44)
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Analysis 1.4. Comparison 1 DHEA versus control (placebo or no treatment), Outcome 4 QoL (subgrouped
on treatment duration).
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 1 DHEA versus control (placebo or no treatment)











IV,Fixed,95% CI IV,Fixed,95% CI
1 <6 weeks
Bloch 2013 0.13 (0.3552) 5.8 % 0.13 [ -0.57, 0.83 ]
Dayal 2005 1.1518 (0.578) 2.2 % 1.15 [ 0.02, 2.28 ]
Finckh 2005 0.1417 (0.2088) 16.9 % 0.14 [ -0.27, 0.55 ]
Subtotal (95% CI) 24.9 % 0.23 [ -0.11, 0.57 ]
Heterogeneity: Chi2 = 2.80, df = 2 (P = 0.25); I2 =29%
Test for overall effect: Z = 1.33 (P = 0.18)
2 6 to 26 weeks
Merritt 2012 0.1314 (0.2044) 17.6 % 0.13 [ -0.27, 0.53 ]
Panjari 2009 0.09 (0.2143) 16.0 % 0.09 [ -0.33, 0.51 ]
Stangl 2010 0.2143 (0.2896) 8.8 % 0.21 [ -0.35, 0.78 ]
Subtotal (95% CI) 42.4 % 0.13 [ -0.13, 0.39 ]
Heterogeneity: Chi2 = 0.12, df = 2 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
3 >26 weeks
Hirshman 2003 0.0195 (0.2582) 11.0 % 0.02 [ -0.49, 0.53 ]
Hirshman 2004 0.4799 (0.5896) 2.1 % 0.48 [ -0.68, 1.64 ]
Kritz-Silverstein 2008 -0.83 (0.1939) 19.6 % -0.83 [ -1.21, -0.45 ]
Subtotal (95% CI) 32.7 % -0.46 [ -0.75, -0.16 ]
Heterogeneity: Chi2 = 9.63, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 3.06 (P = 0.0022)
Total (95% CI) 100.0 % -0.04 [ -0.20, 0.13 ]
Heterogeneity: Chi2 = 24.51, df = 8 (P = 0.002); I2 =67%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi2 = 11.96, df = 2 (P = 0.00), I2 =83%
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Analysis 1.5. Comparison 1 DHEA versus control (placebo or no treatment), Outcome 5 QoL/General
Wellbeing (change scores).
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 1 DHEA versus control (placebo or no treatment)
Outcome: 5 QoL/General Wellbeing (change scores)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Barnhart 1999 33 27.8 (33) 33 31 (82) -0.05 [ -0.53, 0.43 ]
Labrie 2009a 54 3.06 (1.909) 53 0.67 (1.936) 1.23 [ 0.82, 1.65 ]
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Analysis 1.6. Comparison 1 DHEA versus control (placebo or no treatment), Outcome 6 Side-effects.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 1 DHEA versus control (placebo or no treatment)
Outcome: 6 Side-effects
Study or subgroup DHEA placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Androgenic side-effects
Finckh 2005 (1) 11/47 2/45 100.0 % 6.57 [ 1.37, 31.59 ]
Subtotal (95% CI) 47 45 100.0 % 6.57 [ 1.37, 31.59 ]
Total events: 11 (DHEA), 2 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
2 Acne
Bloch 2013 0/14 1/13 51.9 % 0.29 [ 0.01, 7.70 ]
Lasco 2001 1/10 0/10 14.9 % 3.32 [ 0.12, 91.60 ]
Nouveau 2008 1/12 0/10 16.6 % 2.74 [ 0.10, 74.87 ]
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(. . . Continued)
Study or subgroup DHEA placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Panjari 2009 (2) 3/46 0/43 16.5 % 7.00 [ 0.35, 139.60 ]
Subtotal (95% CI) 82 76 100.0 % 2.26 [ 0.56, 9.02 ]
Total events: 5 (DHEA), 1 (placebo)
Heterogeneity: Chi2 = 2.12, df = 3 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
3 Hirsutism
Panjari 2009 2/46 0/43 100.0 % 4.89 [ 0.23, 104.76 ]
Subtotal (95% CI) 46 43 100.0 % 4.89 [ 0.23, 104.76 ]
Total events: 2 (DHEA), 0 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 1.03, df = 2 (P = 0.60), I2 =0.0%
0.005 0.1 1 10 200
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(1) Androgenic side-effects: acne, greasy skin, hirsutism (these were reported total side-effect instead of seperately)
(2) hirsutism also reported in 2/46 women on DHEA and 0 women on placebo but not presented in this data as it was clear if they same women also had acne
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Analysis 1.7. Comparison 1 DHEA versus control (placebo or no treatment), Outcome 7 Acne subgrouped
on study duration.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 1 DHEA versus control (placebo or no treatment)
Outcome: 7 Acne subgrouped on study duration
Study or subgroup DHEA
Placebo/no
treatment Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 < 6 weeks
Bloch 2013 0/14 1/13 100.0 % 0.29 [ 0.01, 7.70 ]
Subtotal (95% CI) 14 13 100.0 % 0.29 [ 0.01, 7.70 ]
Total events: 0 (DHEA), 1 (Placebo/no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
2 >6 weeks to 26 weeks
Nouveau 2008 1/12 0/10 100.0 % 2.74 [ 0.10, 74.87 ]
Subtotal (95% CI) 12 10 100.0 % 2.74 [ 0.10, 74.87 ]
Total events: 1 (DHEA), 0 (Placebo/no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
3 >26 weeks
Lasco 2001 1/10 0/10 47.5 % 3.32 [ 0.12, 91.60 ]
Panjari 2009 3/46 0/43 52.5 % 7.00 [ 0.35, 139.60 ]
Subtotal (95% CI) 56 53 100.0 % 5.25 [ 0.58, 47.36 ]
Total events: 4 (DHEA), 0 (Placebo/no treatment)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Chi2 = 2.09, df = 2 (P = 0.35), I2 =4%
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Analysis 1.8. Comparison 1 DHEA versus control (placebo or no treatment), Outcome 8 Menopausal
symptoms (continuous).
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 1 DHEA versus control (placebo or no treatment)
Outcome: 8 Menopausal symptoms (continuous)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Endscores
Dayal 2005 12 -4.272 (2.3) 5 -5.15 (2.51) 100.0 % 0.35 [ -0.70, 1.40 ]
Subtotal (95% CI) 12 5 100.0 % 0.35 [ -0.70, 1.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 Change scores
Barnhart 1999 33 -70.6 (76) 33 -76.6 (100) 100.0 % 0.07 [ -0.42, 0.55 ]
Subtotal (95% CI) 33 33 100.0 % 0.07 [ -0.42, 0.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
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Analysis 1.9. Comparison 1 DHEA versus control (placebo or no treatment), Outcome 9 Menopausal
symptoms (dichotomous).
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 1 DHEA versus control (placebo or no treatment)
Outcome: 9 Menopausal symptoms (dichotomous)
Study or subgroup DHEA No treatment Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Flushes
Bloch 2013 2/14 1/13 2.00 [ 0.16, 25.11 ]
2 Hot flushes and palpitations
Gupta 2013 4/25 9/25 0.34 [ 0.09, 1.30 ]
3 Insomnia
Gupta 2013 0/25 5/25 0.07 [ 0.00, 1.40 ]
4 Night sweats
Gupta 2013 3/25 10/25 0.20 [ 0.05, 0.87 ]
5 Depression
Gupta 2013 0/25 4/25 0.09 [ 0.00, 1.84 ]
6 Loss of libido
Gupta 2013 0/25 9/25 0.03 [ 0.00, 0.63 ]
7 Vaginal dryness
Gupta 2013 1/25 4/25 0.22 [ 0.02, 2.11 ]
8 Pruritis vulvae
Gupta 2013 1/25 4/25 0.22 [ 0.02, 2.11 ]
9 Urethral syndrome
Gupta 2013 1/25 5/25 0.17 [ 0.02, 1.55 ]
10 Tiredness
Gupta 2013 6/25 15/25 0.21 [ 0.06, 0.71 ]
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Analysis 1.10. Comparison 1 DHEA versus control (placebo or no treatment), Outcome 10 Sexual Function
(end scores).
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 1 DHEA versus control (placebo or no treatment)











IV,Fixed,95% CI IV,Fixed,95% CI
Bloch 2013 0.37 (0.398) 6.7 % 0.37 [ -0.41, 1.15 ]
Dayal 2005 -0.45 (0.5408) 3.6 % -0.45 [ -1.51, 0.61 ]
Finckh 2005 0.419 (0.3127) 10.9 % 0.42 [ -0.19, 1.03 ]
Kritz-Silverstein 2008 (1) -0.08 (0.1888) 29.8 % -0.08 [ -0.45, 0.29 ]
Labrie 2009a 0.42 (0.199) 26.9 % 0.42 [ 0.03, 0.81 ]
Panjari 2009 0.23 (0.2194) 22.1 % 0.23 [ -0.20, 0.66 ]
Total (95% CI) 100.0 % 0.19 [ -0.01, 0.40 ]
Heterogeneity: Chi2 = 5.55, df = 5 (P = 0.35); I2 =10%
Test for overall effect: Z = 1.88 (P = 0.060)
Test for subgroup differences: Not applicable
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(1) sensitivity analysis without study - result are and hetero
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Analysis 1.11. Comparison 1 DHEA versus control (placebo or no treatment), Outcome 11 Sexual function
(end scores) (sensitivity analysis).
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 1 DHEA versus control (placebo or no treatment)











IV,Fixed,95% CI IV,Fixed,95% CI
Bloch 2013 0.37 (0.398) 9.6 % 0.37 [ -0.41, 1.15 ]
Dayal 2005 -0.45 (0.5408) 5.2 % -0.45 [ -1.51, 0.61 ]
Finckh 2005 0.419 (0.3127) 15.5 % 0.42 [ -0.19, 1.03 ]
Labrie 2009a 0.42 (0.199) 38.3 % 0.42 [ 0.03, 0.81 ]
Panjari 2009 0.23 (0.2194) 31.5 % 0.23 [ -0.20, 0.66 ]
Total (95% CI) 100.0 % 0.31 [ 0.07, 0.55 ]
Heterogeneity: Chi2 = 2.56, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Oral DHEA versus control subgrouped by route of administration, Outcome 1
QoL/wellbeing (change scores).
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 2 Oral DHEA versus control subgrouped by route of administration
Outcome: 1 QoL/wellbeing (change scores)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Oral administration
Barnhart 1999 33 27.8 (33) 33 31 (82) 100.0 % -0.05 [ -0.53, 0.43 ]
Subtotal (95% CI) 33 33 100.0 % -0.05 [ -0.53, 0.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.84)
2 Intravaginal application
Labrie 2009a 54 3.06 (1.909) 53 0.67 (1.936) 100.0 % 1.23 [ 0.82, 1.65 ]
Subtotal (95% CI) 54 53 100.0 % 1.23 [ 0.82, 1.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.83 (P < 0.00001)
Test for subgroup differences: Chi2 = 15.66, df = 1 (P = 0.00), I2 =94%
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Analysis 2.2. Comparison 2 Oral DHEA versus control subgrouped by route of administration, Outcome 2
Side-effects: acne.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 2 Oral DHEA versus control subgrouped by route of administration
Outcome: 2 Side-effects: acne
Study or subgroup DHEA Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Skin application
Nouveau 2008 1/12 0/10 16.6 % 2.74 [ 0.10, 74.87 ]
Subtotal (95% CI) 12 10 16.6 % 2.74 [ 0.10, 74.87 ]
Total events: 1 (DHEA), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
2 Oral administration
Bloch 2013 0/14 1/13 51.9 % 0.29 [ 0.01, 7.70 ]
Lasco 2001 1/10 0/10 14.9 % 3.32 [ 0.12, 91.60 ]
Panjari 2009 3/46 0/43 16.5 % 7.00 [ 0.35, 139.60 ]
Subtotal (95% CI) 70 66 83.4 % 2.16 [ 0.47, 9.96 ]
Total events: 4 (DHEA), 1 (Placebo)
Heterogeneity: Chi2 = 2.10, df = 2 (P = 0.35); I2 =5%
Test for overall effect: Z = 0.99 (P = 0.32)
Total (95% CI) 82 76 100.0 % 2.26 [ 0.56, 9.02 ]
Total events: 5 (DHEA), 1 (Placebo)
Heterogeneity: Chi2 = 2.12, df = 3 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
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Analysis 2.4. Comparison 2 Oral DHEA versus control subgrouped by route of administration, Outcome 4
Sexual Function (end scores).
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 2 Oral DHEA versus control subgrouped by route of administration











IV,Fixed,95% CI IV,Fixed,95% CI
1 Oral administration
Bloch 2013 0.37 (0.398) 6.7 % 0.37 [ -0.41, 1.15 ]
Dayal 2005 -0.45 (0.5408) 3.6 % -0.45 [ -1.51, 0.61 ]
Finckh 2005 0.419 (0.3127) 10.9 % 0.42 [ -0.19, 1.03 ]
Kritz-Silverstein 2008 (1) -0.08 (0.1888) 29.8 % -0.08 [ -0.45, 0.29 ]
Panjari 2009 0.23 (0.2194) 22.1 % 0.23 [ -0.20, 0.66 ]
Subtotal (95% CI) 73.1 % 0.11 [ -0.13, 0.35 ]
Heterogeneity: Chi2 = 3.79, df = 4 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
2 Intravaginal application
Labrie 2009a 0.42 (0.199) 26.9 % 0.42 [ 0.03, 0.81 ]
Subtotal (95% CI) 26.9 % 0.42 [ 0.03, 0.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
Total (95% CI) 100.0 % 0.19 [ -0.01, 0.40 ]
Heterogeneity: Chi2 = 5.55, df = 5 (P = 0.35); I2 =10%
Test for overall effect: Z = 1.88 (P = 0.060)
Test for subgroup differences: Chi2 = 1.77, df = 1 (P = 0.18), I2 =43%
-2 -1 0 1 2
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Analysis 3.1. Comparison 3 DHEA versus HT, Outcome 1 QoL/General Wellbeing.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 3 DHEA versus HT
Outcome: 1 QoL/General Wellbeing





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ET
Dayal 2005 12 16.731 (3.18) 5 15.1 (3.93) 1.63 [ -2.25, 5.52 ]
2 Combined
3 Tibolone
-4 -2 0 2 4
Favours DHEA Favours HT
Analysis 3.3. Comparison 3 DHEA versus HT, Outcome 3 Menopausal symptoms (continuous).
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 3 DHEA versus HT
Outcome: 3 Menopausal symptoms (continuous)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ET
Stomati 1999 8 -4.75 (4.2426) 6 -3 (4.654) -0.37 [ -1.44, 0.70 ]
2 Combined
Genazzani 2011 12 -8 (1) 12 -9 (0.9) 1.01 [ 0.16, 1.87 ]
3 Tibolone
Genazzani 2011 12 -8 (1) 12 -9 (0.8) 1.07 [ 0.20, 1.93 ]
-2 -1 0 1 2
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Analysis 3.4. Comparison 3 DHEA versus HT, Outcome 4 Sexual Function.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 3 DHEA versus HT
Outcome: 4 Sexual Function





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ET/ET+P
Dayal 2005 12 5.0463 (1.66) 5 3.72 (1.53) 80.5 % 1.32 [ -0.31, 2.96 ]
Genazzani 2011 12 48.6 (4.6) 12 47.6 (3.66) 19.5 % 1.00 [ -2.33, 4.33 ]
Subtotal (95% CI) 24 17 100.0 % 1.26 [ -0.21, 2.73 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.093)
2 Tibolone
Genazzani 2011 12 48.6 (4.6) 12 44 (4.6) 100.0 % 4.60 [ 0.92, 8.28 ]
Subtotal (95% CI) 12 12 100.0 % 4.60 [ 0.92, 8.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Chi2 = 2.73, df = 1 (P = 0.10), I2 =63%
-10 -5 0 5 10
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Analysis 4.1. Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 1 Acne.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 4 DHEA versus HT (side effects) (dichotomous)
Outcome: 1 Acne
Study or subgroup DHEA HT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ET
Gupta 2013 6/25 0/25 100.0 % 17.00 [ 0.90, 320.37 ]
Subtotal (95% CI) 25 25 100.0 % 17.00 [ 0.90, 320.37 ]
Total events: 6 (DHEA), 0 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
2 Tibolone
Gupta 2013 6/25 0/25 100.0 % 17.00 [ 0.90, 320.37 ]
Subtotal (95% CI) 25 25 100.0 % 17.00 [ 0.90, 320.37 ]
Total events: 6 (DHEA), 0 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 4.2. Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 2 Hair loss.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 4 DHEA versus HT (side effects) (dichotomous)
Outcome: 2 Hair loss
Study or subgroup DHEA HT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ET
Gupta 2013 4/25 0/25 100.0 % 10.67 [ 0.54, 209.64 ]
Subtotal (95% CI) 25 25 100.0 % 10.67 [ 0.54, 209.64 ]
Total events: 4 (DHEA), 0 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
2 Tibolone
Gupta 2013 4/25 0/25 100.0 % 10.67 [ 0.54, 209.64 ]
Subtotal (95% CI) 25 25 100.0 % 10.67 [ 0.54, 209.64 ]
Total events: 4 (DHEA), 0 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 4.3. Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 3 Headache.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 4 DHEA versus HT (side effects) (dichotomous)
Outcome: 3 Headache
Study or subgroup DHEA HT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ET
Gupta 2013 0/25 10/25 100.0 % 0.03 [ 0.00, 0.53 ]
Subtotal (95% CI) 25 25 100.0 % 0.03 [ 0.00, 0.53 ]
Total events: 0 (DHEA), 10 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 2.39 (P = 0.017)
2 Tibolone
Gupta 2013 0/25 2/25 100.0 % 0.18 [ 0.01, 4.04 ]
Subtotal (95% CI) 25 25 100.0 % 0.18 [ 0.01, 4.04 ]
Total events: 0 (DHEA), 2 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Chi2 = 0.73, df = 1 (P = 0.39), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 4.4. Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 4 Nausea.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 4 DHEA versus HT (side effects) (dichotomous)
Outcome: 4 Nausea
Study or subgroup DHEA HT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ET
Gupta 2013 2/25 7/25 100.0 % 0.22 [ 0.04, 1.21 ]
Subtotal (95% CI) 25 25 100.0 % 0.22 [ 0.04, 1.21 ]
Total events: 2 (DHEA), 7 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.082)
2 Tibolone
Gupta 2013 2/25 2/25 100.0 % 1.00 [ 0.13, 7.72 ]
Subtotal (95% CI) 25 25 100.0 % 1.00 [ 0.13, 7.72 ]
Total events: 2 (DHEA), 2 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 1.23, df = 1 (P = 0.27), I2 =18%
0.01 0.1 1 10 100
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Analysis 4.5. Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 5 Leg cramps.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 4 DHEA versus HT (side effects) (dichotomous)
Outcome: 5 Leg cramps
Study or subgroup DHEA HT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ET
Gupta 2013 0/25 0/25 Not estimable
Subtotal (95% CI) 25 25 Not estimable
Total events: 0 (DHEA), 0 (HT)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Tibolone
Gupta 2013 0/25 0/25 Not estimable
Subtotal (95% CI) 25 25 Not estimable
Total events: 0 (DHEA), 0 (HT)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 4.6. Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 6 Breast Tenderness.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 4 DHEA versus HT (side effects) (dichotomous)
Outcome: 6 Breast Tenderness
Study or subgroup DHEA HT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ET
Gupta 2013 0/25 5/25 100.0 % 0.07 [ 0.00, 1.40 ]
Subtotal (95% CI) 25 25 100.0 % 0.07 [ 0.00, 1.40 ]
Total events: 0 (DHEA), 5 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.082)
2 Tibolone
Gupta 2013 0/25 1/25 100.0 % 0.32 [ 0.01, 8.25 ]
Subtotal (95% CI) 25 25 100.0 % 0.32 [ 0.01, 8.25 ]
Total events: 0 (DHEA), 1 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 0.44, df = 1 (P = 0.51), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 4.7. Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 7 Bloating.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 4 DHEA versus HT (side effects) (dichotomous)
Outcome: 7 Bloating
Study or subgroup DHEA HT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ET
Gupta 2013 0/25 4/25 100.0 % 0.09 [ 0.00, 1.84 ]
Subtotal (95% CI) 25 25 100.0 % 0.09 [ 0.00, 1.84 ]
Total events: 0 (DHEA), 4 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
2 Tibolone
Gupta 2013 0/25 2/25 100.0 % 0.18 [ 0.01, 4.04 ]
Subtotal (95% CI) 25 25 100.0 % 0.18 [ 0.01, 4.04 ]
Total events: 0 (DHEA), 2 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.76), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 4.8. Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 8 Weight gain.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 4 DHEA versus HT (side effects) (dichotomous)
Outcome: 8 Weight gain
Study or subgroup DHEA HT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ET
Gupta 2013 0/25 4/25 100.0 % 0.09 [ 0.00, 1.84 ]
Subtotal (95% CI) 25 25 100.0 % 0.09 [ 0.00, 1.84 ]
Total events: 0 (DHEA), 4 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
2 Tibolone
Gupta 2013 0/25 2/25 100.0 % 0.18 [ 0.01, 4.04 ]
Subtotal (95% CI) 25 25 100.0 % 0.18 [ 0.01, 4.04 ]
Total events: 0 (DHEA), 2 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.76), I2 =0.0%
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Analysis 5.1. Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 1
Tiredness.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 5 DHEA versus HT (menopausal symptoms) (dichotomous)
Outcome: 1 Tiredness
Study or subgroup DHEA HT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ET
Gupta 2013 6/25 5/25 50.0 % 1.26 [ 0.33, 4.84 ]
Subtotal (95% CI) 25 25 50.0 % 1.26 [ 0.33, 4.84 ]
Total events: 6 (DHEA), 5 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
2 Tibolone
Gupta 2013 6/25 5/25 50.0 % 1.26 [ 0.33, 4.84 ]
Subtotal (95% CI) 25 25 50.0 % 1.26 [ 0.33, 4.84 ]
Total events: 6 (DHEA), 5 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
Total (95% CI) 50 50 100.0 % 1.26 [ 0.49, 3.26 ]
Total events: 12 (DHEA), 10 (HT)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 5.2. Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 2 Hot
flushes and palpitations.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 5 DHEA versus HT (menopausal symptoms) (dichotomous)
Outcome: 2 Hot flushes and palpitations
Study or subgroup DHEA HT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ET
Gupta 2013 4/25 3/25 100.0 % 1.40 [ 0.28, 7.00 ]
Subtotal (95% CI) 25 25 100.0 % 1.40 [ 0.28, 7.00 ]
Total events: 4 (DHEA), 3 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
2 Tibolone
Gupta 2013 4/25 3/25 100.0 % 1.40 [ 0.28, 7.00 ]
Subtotal (95% CI) 25 25 100.0 % 1.40 [ 0.28, 7.00 ]
Total events: 4 (DHEA), 3 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 5.3. Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 3 Night
sweats.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 5 DHEA versus HT (menopausal symptoms) (dichotomous)
Outcome: 3 Night sweats
Study or subgroup DHEA HT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ET
Gupta 2013 3/25 3/25 100.0 % 1.00 [ 0.18, 5.51 ]
Subtotal (95% CI) 25 25 100.0 % 1.00 [ 0.18, 5.51 ]
Total events: 3 (DHEA), 3 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Tibolone
Gupta 2013 3/25 4/25 100.0 % 0.72 [ 0.14, 3.59 ]
Subtotal (95% CI) 25 25 100.0 % 0.72 [ 0.14, 3.59 ]
Total events: 3 (DHEA), 4 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.78), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 5.4. Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 4 Vaginal
Dryness.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 5 DHEA versus HT (menopausal symptoms) (dichotomous)
Outcome: 4 Vaginal Dryness
Study or subgroup DHEA HT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ET
Gupta 2013 1/25 1/25 100.0 % 1.00 [ 0.06, 16.93 ]
Subtotal (95% CI) 25 25 100.0 % 1.00 [ 0.06, 16.93 ]
Total events: 1 (DHEA), 1 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Tibolone
Gupta 2013 1/25 0/25 100.0 % 3.12 [ 0.12, 80.39 ]
Subtotal (95% CI) 25 25 100.0 % 3.12 [ 0.12, 80.39 ]
Total events: 1 (DHEA), 0 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 0.27, df = 1 (P = 0.60), I2 =0.0%
0.01 0.1 1 10 100
Favours DHEA Favours HT
107Dehydroepiandrosterone for women in the peri- or postmenopausal phase (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.5. Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 5 Pruritis
Vulvae.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 5 DHEA versus HT (menopausal symptoms) (dichotomous)
Outcome: 5 Pruritis Vulvae
Study or subgroup DHEA HT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ET
Gupta 2013 1/25 1/25 100.0 % 1.00 [ 0.06, 16.93 ]
Subtotal (95% CI) 25 25 100.0 % 1.00 [ 0.06, 16.93 ]
Total events: 1 (DHEA), 1 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Tibolone
Gupta 2013 1/25 0/25 100.0 % 3.12 [ 0.12, 80.39 ]
Subtotal (95% CI) 25 25 100.0 % 3.12 [ 0.12, 80.39 ]
Total events: 1 (DHEA), 0 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 0.27, df = 1 (P = 0.60), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 5.6. Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 6
Urethral Syndrome.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 5 DHEA versus HT (menopausal symptoms) (dichotomous)
Outcome: 6 Urethral Syndrome
Study or subgroup DHEA HT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ET
Gupta 2013 1/25 2/25 100.0 % 0.48 [ 0.04, 5.65 ]
Subtotal (95% CI) 25 25 100.0 % 0.48 [ 0.04, 5.65 ]
Total events: 1 (DHEA), 2 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 Tibolone
Gupta 2013 1/25 1/25 100.0 % 1.00 [ 0.06, 16.93 ]
Subtotal (95% CI) 25 25 100.0 % 1.00 [ 0.06, 16.93 ]
Total events: 1 (DHEA), 1 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 5.7. Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 7
Depression.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 5 DHEA versus HT (menopausal symptoms) (dichotomous)
Outcome: 7 Depression
Study or subgroup DHEA HT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ET
Gupta 2013 0/25 1/25 100.0 % 0.32 [ 0.01, 8.25 ]
Subtotal (95% CI) 25 25 100.0 % 0.32 [ 0.01, 8.25 ]
Total events: 0 (DHEA), 1 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 Tibolone
Gupta 2013 0/25 0/25 Not estimable
Subtotal (95% CI) 25 25 Not estimable
Total events: 0 (DHEA), 0 (HT)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 5.8. Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 8 Loss of
libido.
Review: Dehydroepiandrosterone for women in the peri- or postmenopausal phase
Comparison: 5 DHEA versus HT (menopausal symptoms) (dichotomous)
Outcome: 8 Loss of libido
Study or subgroup DHEA HT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ET
Gupta 2013 0/25 1/25 100.0 % 0.32 [ 0.01, 8.25 ]
Subtotal (95% CI) 25 25 100.0 % 0.32 [ 0.01, 8.25 ]
Total events: 0 (DHEA), 1 (HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 Tibolone
Gupta 2013 0/25 0/25 Not estimable
Subtotal (95% CI) 25 25 Not estimable
Total events: 0 (DHEA), 0 (HT)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Menstrual Disorders and Subfertility Group search strategy (PROCITE platform)
Menstrual Disorders and Subfertility (MDSG) database search.
Keywords CONTAINS “menopausal”or“*Menopause”or“perimenopause”or“perimenopausal”or “Postmenopausal”or “post-
menopause”or“climacteric ”or “vasomotor”or“hot flashes”or “hot flushes”or“vaginal atrophy”or “vaginal dryness” or “night sweats”or
“night sweats-outcome”or“night time awakenings”or “nocturnal diaphoresis”or“sexual function”or“sexual fuctioning”or “Sexual func-
tioning”or “sexual satisfaction” or Title CONTAINS “menopausal”or“*Menopause”or“perimenopause”or“perimenopausal”or “Post-
menopausal”or “postmenopause”or“climacteric ”or “vasomotor”or“hot flashes”or “hot flushes”or“vaginal atrophy”or “vaginal dryness”
or “night sweats”or “night sweats-outcome”or“night time awakenings”or “nocturnal diaphoresis”or“sexual function”or“sexual fuction-
ing”or “Sexual functioning”or “sexual satisfaction”
AND
Keywords CONTAINS “DHEA”or “DHEAS” or“dehydroepiandrosterone”or “androstenedione” or “Prasterone” or Title CONTAINS
“DHEA”or “DHEAS” or“dehydroepiandrosterone”or “androstenedione” or “Prasterone”
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Appendix 2. CENTRAL search strategy (Ovid platform)
From inception to 10 February 2014; search updated on 3 June 2014
Database: EBM Reviews - Cochrane Central Register of Controlled Trials
1 (climacteric or menopaus$).tw. (4318)
2 (postmenopaus$ or perimenopaus$).tw. (8532)
3 vasomotor.tw. (899)
4 exp Menopause, Premature/ or exp Menopause/ (5295)
5 exp Climacteric/ (5514)
6 exp Perimenopause/ (62)
7 exp Postmenopause/ (3510)
8 exp Hot Flashes/ (457)
9 (hot flash$ or hot flush$).tw. (1014)
10 night sweat$.tw. (107)
11 Nocturnal diaphoresis.tw. (2)
12 vagina$ dry$.tw. (119)
13 sexual function$.tw. (931)
14 sexual satisfaction.tw. (149)
15 vagina$ atrophy.tw. (80)
16 or/1-15 (13614)






23 dha sulfate.tw. (1)
24 androstenolone.tw. (3)
25 or/17-24 (1028)
26 16 and 25 (213)
Appendix 3. MEDLINE search strategy (Ovid platform)
From inception to 10 February 2014; search updated on 3 June 2014
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
<1946 to Present>
1 (climacteric or menopaus$).tw. (37286)
2 (postmenopaus$ or perimenopaus$).tw. (42140)
3 vasomotor.tw. (10342)
4 exp Menopause, Premature/ or exp Menopause/ (44481)
5 exp Climacteric/ (47888)
6 exp Perimenopause/ (748)
7 exp Postmenopause/ (18274)
8 exp Hot Flashes/ (2212)
9 (hot flash$ or hot flush$).tw. (3446)
10 night sweat$.tw. (1409)
11 Nocturnal diaphoresis.tw. (7)
12 vagina$ dry$.tw. (617)
13 sexual function$.tw. (8686)
14 sexual satisfaction.tw. (1342)
15 vagina$ atrophy.tw. (309)
16 or/1-15 (101033)
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23 dha sulfate.tw. (54)
24 androstenolone.tw. (59)
25 or/17-24 (19764)
26 16 and 25 (1887)
27 randomized controlled trial.pt. (360999)




32 clinical trials as topic.sh. (166848)
33 randomly.ab. (205060)
34 trial.ti. (120220)
35 (crossover or cross-over or cross over).tw. (58959)
36 or/27-35 (912453)
37 exp animals/ not humans.sh. (3871615)
38 36 not 37 (841156)
39 26 and 38 (281)
Appendix 4. EMBASE search strategy (Ovid platform)
From inception to 10 February 2014; search updated on 3 June 2014
Database: Embase
1 exp menopause/ or exp early menopause/ or exp menopause related disorder/ or exp “menopause and climacterium”/ (98833)
2 exp climacterium/ (7155)
3 exp postmenopause bleeding/ or exp postmenopause/ or exp postmenopause osteoporosis/ (54600)
4 exp hot flush/ (11311)
5 (climacteric or menopaus$).tw. (51753)
6 (postmenopaus$ or perimenopaus$).tw. (56450)
7 vasomotor.tw. (12370)
8 (hot flash$ or hot flush$).tw. (4839)
9 night sweat$.tw. (2592)
10 Nocturnal diaphoresis.tw. (11)
11 vagina$ dry$.tw. (993)
12 sexual function$.tw. (12965)
13 sexual satisfaction.tw. (2075)
14 or/1-13 (153865)






21 dha sulfate.tw. (49)
22 androstenolone.tw. (48)
23 or/15-22 (23993)
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24 14 and 23 (2738)
25 Clinical Trial/ (893176)
26 Randomized Controlled Trial/ (367106)
27 exp randomization/ (64837)
28 Single Blind Procedure/ (18996)
29 Double Blind Procedure/ (120415)
30 Crossover Procedure/ (39883)
31 Placebo/ (235150)
32 Randomi?ed controlled trial$.tw. (100442)
33 Rct.tw. (13654)
34 random allocation.tw. (1338)
35 randomly allocated.tw. (20433)
36 allocated randomly.tw. (1956)
37 (allocated adj2 random).tw. (745)
38 Single blind$.tw. (14429)
39 Double blind$.tw. (144232)
40 ((treble or triple) adj blind$).tw. (359)
41 placebo$.tw. (201652)
42 prospective study/ (263739)
43 or/25-42 (1415726)
44 case study/ (24045)
45 case report.tw. (261912)
46 abstract report/ or letter/ (904483)
47 or/44-46 (1184797)
48 43 not 47 (1377829)
49 24 and 48 (672)
Appendix 5. PsycINFO search strategy (Ovid platform)
From inception to 10 February 2014; search updated on 3 June 2014
Database: PsycINFO
1 exp Menopause/ (2848)
2 (climacteric or menopaus$).tw. (3823)
3 (postmenopaus$ or perimenopaus$).tw. (2229)
4 vasomotor.tw. (1149)
5 (hot flash$ or hot flush$).tw. (436)
6 night sweat$.tw. (110)
7 Nocturnal diaphoresis.tw. (1)
8 vagina$ dry$.tw. (107)
9 sexual function$.tw. (3897)
10 sexual satisfaction.tw. (1500)







18 dha sulfate.tw. (1)
19 androstenolone.tw. (1)
20 or/13-19 (1022)
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25 clinical trials/ (7255)
26 placebo/ (3679)
27 exp Treatment/ (566963)
28 or/22-27 (865080)
29 21 and 28 (53)
Appendix 6. CINAHL search strategy (EBSCO platform)
From inception to 10 February 2014; search updated on 3 June 2014
# Query Results
S22 S15 AND S21 230
S21 S16 OR S17 OR S18 OR S19 OR S20 1,246
S20 TX androstenedione 262
S19 TX Prasterone 18
S18 TX DHEA 366
S17 TX Dehydroepiandrosterone 1,064
S16 (MM “Dehydroepiandrosterone”) 390
S15 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR
S9 OR S10 OR S11 OR S12 OR S13 OR S14
25,518
S14 TX Nocturnal diaphoresis 1
S13 TX sexual satisfaction 1,056
S12 TX sexual function* 2,371
S11 TX vagina* atrophy 128
S10 TX vagina* dry* 230
S9 TX night sweat* 345
S8 TX hot flush* 466
S7 TX hot flash* 2,018
S6 TX Climacteri* 1,659
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(Continued)
S5 (MH “Climacteric+”) OR (MH “Hot Flashes”) 15,561
S4 TX perimenopaus* 3,096
S3 TX postmenopaus* 11,557
S2 TX Menopaus* 11,502
S1 (MH “Menopause+”) OR (MM “Menopause, Premature”)
OR (MM “Perimenopause”) OR (MM “Postmenopause”)
13,395
Appendix 7. Search strategies for other databases
The search strategy for trials registers






The search strategy for DARE (Database of Abstracts of Reviews of Effects)
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CS - drafted protocol and full review text, abstract and full text screening and data extraction
SA - read, adjusted and approved draft, main part of abstracts and full text screening and data extraction
AC - read, adjusted and approved draft, abstracts and full text screening
CF - provided expert advice on background, read and adjusted draft
VJ - provided methodological advice as well having read, adjusted and approved draft
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External sources
• Groninger Universiteitsfonds, Netherlands.
Internship Funding
• RIjksuniversiteit Groningen, Netherlands.
Marco Polo Funding/Internship funding
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The title has been changed from: “Dehydroepiandrosterone for menopausal women” to “Dehydroepiandrosterone for women in the
peri- and postmenopausal phase” as these terms were more woman-centred. Objectives were changed from “women with menopausal
symptoms” into “women in the peri- or postmenopausal phase”. We found “women in the peri- and postmenopausal phase” described
our study population better, as menopausal symptoms were not our main outcome.
For assessment of adverse effects we assessed cardiovascular risk and breast cancer risk by measuring the frequency of cardiovascular
events and breast cancer events in trials. This was not specified in the protocol. We did not assess other cardiovascular risk parameters
or breast cancer parameters.
We replaced ’hormone replacement therapy’ with ’hormone therapy’. Tibolone (a synthesized hormone) has been added to hormone
therapy but has been separated from estrogen (with or without progestin) therapies.
We chose to include an additional subgroup analysis looking at route of administration as we were unable to conduct a direct comparison
of different application route as planned. We chose to do a sensitivity analysis for our secondary outcome sexual function as well
(excluding studies with a high risk of bias) as we judged the remaining results to be more accurate and more reliable.
None of these changes were made as a result of the findings of included studies, but to improve the structure of the review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acne Vulgaris [chemically induced]; Dehydroepiandrosterone [adverse effects; ∗therapeutic use]; Dyspareunia [drug therapy]; Estrogens
[blood]; Hot Flashes [drug therapy]; Perimenopause [blood; ∗drug effects]; Postmenopause [blood; ∗drug effects]; Quality of Life;
Randomized Controlled Trials as Topic; Selection Bias; Sweating [drug effects]
MeSH check words
Female; Humans
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